Monthly Archives: October 2019

Nanoparticles could be a promising candidate for asthma therapy

DOI: 10.31038/NAMS.2019231

Nanomedicine and asthma

Nanotechnology has been fundamental for respiratory medicine for various reasons; like exhibiting novel approaches in treating respiratory diseases and its applications in cosmetics, consumer products and medications which are continuously rising as well as therapeutic vaccinations. Additionally, it is being developed commercially to bring the new approach to patients [1]. Over the years many efforts are done to adopt nanotechnology for the treatment of human respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma. Asthma is a widespread heterogeneous, complex disease which affects about 300 million people around the world. This chronic inflammatory disease is characterized by airway hyperreactivity, mucus hypersecretion in the airways, and recurrent obstructive respiratory events in response to asthma “triggers [2].

Initially, asthma studies were restricted to mice, but the technology is progressing to clinical experiments. A clinical trial using nanoparticles has uncovered some of the reasons of chronic lung diseases, as ways to prevent and treat these diseases.

These nanoparticles can act as carriers for different drugs because they are so tiny to reach nearly every area and part of the human organism. Drugs can also be tied to the nanoparticles by a plenty of different linkers such as molecules or by encapsulation, which leads to better control of toxicokinetics [1].

Immunotherapy in asthma

Recently, research of allergen-specific immunotherapy (AIT) with nanoparticles (NPs) provides an effective and safe way for the treatment of allergic diseases [3]. It has been proved that encapsulation of DNA vaccines or allergens into nanostructures may provide promising results for the treatment of allergic asthma compared to the conventional AIT with noncapsulated allergen extracts [3]. Moreover, the approval of cytokine-targeting therapy like anti-IgE antibody for the treatment of asthma helped to develop novel biologicals that target T-helper Th1/Th2 interleukins; (IL)-4, IL-5, IL-13, IL-17, and IL-23 and also the epithelium-derived cytokines; IL-25, IL-33, and thymic stromal lymphopoietin [2].

PEGylated and citrated gold nanoparticles (Au)

Because of their unique and physicochemical features and availability, gold nanoparticles were used in early nanotechnology applications and stayed a contemporary research theme, with both Aurimmune (Cyt-6091) and AuroShell based on gold nanoparticles [4]. Au nanoparticles have numerous features that are attractive for use in cancer therapy; they can bind many drugs and proteins and can be targeted to tumor cells. They are tiny enough to penetrate the body and accumulate in tumors to enhance permeability and retention (EPR) effect [5].

Moreover, Omlor et al. [6] reported in their ovalbumin-induced airway inflammation study that gold nanoparticles have anti-inflammatory effect. Dispersions of both polyethylene‐glycol‐coated (PEGylated) and citrate/tannic‐acid‐coated (citrated) gold nanoparticles were applied by intranasal route to asthma and control mice. Particularly citrated gold nanoparticles inhibited both airway hyperreactivity and inflammatory infiltrates. The results suggested that gold nanoparticle-based asthma drugs could have therapeutic potential [6].

A novel anti-IL4Rα nanoparticle; superparamagnetic iron oxide nanoparticles (SPION)

Among different drug nano-carriers, superparamagnetic iron oxide nanoparticles (SPIONs) have shown promising potential in the field of nanomedicine. SPIONs have the highest drug targeting efficiency among other drug carriers, since their external magnetic surface applied to the target organs promotes the accumulation of magnetic nanoscales in the drug site of action [7].

Moreover, they have been used in preclinical applications like magnetic resonance imaging (MRI), hyperthermia, immunoassays, cell tracking, and drug delivery [8]. When iron oxide nanoparticles enter the body, they have the ability to interact with biological compounds such as proteins and cells; leading to distribution of NPs into different organs and tissues [9].

Recently, many strategies aimed to block IL4Rα, the receptor for a key pro-inflammatory pathway. Halwani et al. [10] reported that PEGylated dextran SPION conjugated to anti-IL4Rα blocking antibodies (anti-IL4Rα NPs) efficiently suppressed lung inflammation in a mice model of asthma. Interestingly, exposure to these nanoparticles deactivated CD4 and CD8 T cells and inhibited their ability to produce pro-inflammatory cytokines in murine lung tissue. Moreover, the number of immune cells; lymphocytes, neutrophils and eosinophils were also reduced [10].

These findings suggested that biological molecules targeting IL4Rα might supply a novel therapeutic modality, mostly for patients suffering from uncontrolled, severe asthma [11] [12].

Hydroxybenzyl alcohol (HBA)-incorporated polyoxalate nanoparticles (HPOX)

p-Hydroxybenzyl alcohol (HBA) was defined as one of phenolic compounds in herbal agents and has an important role in protection against oxidative damage-relative pathologies due to its anti-inflammatory properties [13]. Yoo et al. reported a category of fully biodegradable hydroxybenzyl alcohol (HBA)-incorporated polyoxalate (HPOX) as a new therapeutics of airway inflammatory diseases [14].

This anti-asthmatic effect was shown in a mouse model by decreasing the expression of pro-inflammatory mediators like iNOS and IL-4 and the recruitment of inflammatory cells. Moreover, these nanoparticles showed high potent anti-inflammatory and antioxidant influences by decreasing the generation of oxidative stress, scavenging H2O2 and inhibition the expression of pro inflammatory cytokines such as IL-1β, inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) in activated macrophages [14].

Due to their superior anti-inflammatory, antioxidant, and anti-asthmatic properties, HPOX nanoparticles could have a major potential as drug transporter and therapeutics for the handling of asthma and other airway inflammatory diseases like COPD [14].

Curcumin-solid lipid nanoparticles (curcumin-SLNs)

Curcumin has unique pharmacological properties including the anti-inflammatory effect, however, its fast metabolization and low bioavailability have restricted its usage [15]. In asthma experimental rat model, curcumin-SLNs effectively suppressed inflammatory cell infiltration and airway hyperresponsiveness and also prevented the production of Th2 cytokines, including IL-4 and IL-13 [15]. These findings suggest that curcumin-SLNs can be a potential candidate for the treatment of allergic diseases like asthma [15].

Conclusion

Asthma is a widespread, chronic inflammatory, heterogeneous, and obstructive pulmonary disease. Nanoscale based drug delivery systems can offer great potential for modern therapeutics. This work summarizes some nanoparticles that are likely to show pharmacological efficacy targeting airway inflammation.

Many promising nano based drugs are currently undergoing clinical trials to be used as novel therapies against diseases such as lung cancer, COPD, and pulmonary fibrosis.

References

  1. Omlor AJ, Nguyen J, Bals R, Dinh QT (2015) Nanotechnology in respiratory medicine. Respir Res 16: 64.
  2. Heck S, Nguyen J, Le DD, Bals R, Dinh QT (2015) Pharmacological Therapy of Bronchial Asthma: The Role of Biologicals. Int Arch Allergy Immunol 168: 241–252.
  3. Pohlit H, Bellinghausen I, Frey H, Saloga J (2017) Recent advances in the use of nanoparticles for allergen-specific immunotherapy. Allergy 72: 1461–1474.
  4. Khlebtsov N, Dykman L (2011) Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem Soc Rev 40: 1647–1671.
  5. Jain S, Coulter JA, Butterworth KT, Hounsell AR, McMahon SJ, et al.(2014) Gold nanoparticle cellular uptake, toxicity and radiosensitisation in hypoxic conditions. Radiother Oncol 110: 342–347.
  6. Omlor AJ, Le DD, Schlicker J, Hannig M, Ewen R, Heck S, et al. (2017) Local Effects on Airway Inflammation and Systemic Uptake of 5 nm PEGylated and Citrated Gold Nanoparticles in Asthmatic Mice. Small.
  7. Laurent S, Saei AA, Behzadi S, Panahifar A, Mahmoudi M (2014) Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: opportunities and challenges. Expert Opin Drug Deliv 11: 1449–1470.
  8. Dulinska-Litewka J, Lazarczyk A, Halubiec P, Szafranski O, Karnas K, Karewicz A (2019) Superparamagnetic Iron Oxide Nanoparticles-Current and Prospective Medical Applications. Materials (Basel) 12.
  9. Kim JS, Yoon TJ, Yu KN, Kim BG, Park SJ, Kim HW, et al. (2006) Toxicity and tissue distribution of magnetic nanoparticles in mice. Toxicol Sci 89: 338–347.
  10. Halwani R, Sultana SA, Ratemi E, Afzal S, Kenana R, Al-Muhsen S, et al. (2016) A novel anti-IL4Ralpha nanoparticle efficiently controls lung inflammation during asthma. Exp Mol Med 48: e262.
  11. Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, et al. (2010) A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 181: 788–796.
  12. Brightling CE, Saha S, Hollins F (2010) Interleukin-13: prospects for new treatments. Clin Exp Allergy 40: 42–49.
  13. Park H, Kim S, Kim S, Song Y, Seung K, Hong D, et al. (2010) Antioxidant and anti-inflammatory activities of hydroxybenzyl alcohol releasing biodegradable polyoxalate nanoparticles. Biomacromolecules 11: 2103–2108.
  14. Yoo D, Guk K, Kim H, Khang G, Wu D, Lee D (2013) Antioxidant polymeric nanoparticles as novel therapeutics for airway inflammatory diseases. Int J Pharm  450: 87–94.
  15. Wang W, Zhu R, Xie Q, Li A, Xiao Y, Li K, et al. (2012) Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int J Nanomedicine 7: 3667–3677.

Malaria: It’s Gynecological and Obstretic Effects on Humans – A Short Note

DOI: 10.31038/IGOJ.2019242

Short Commentary

Malaria is a vector borne disease of man caused by protozoans of the genus Plasmodium – P. vivax, P.ovale, P. malariae, P. falciparum and, more recently, P. knowlesi [1]. These parasites are present within the red blood cells, and they are transmitted by mosquitoes of the genus Anopheles.

Considering the medical importance of malaria in the context of the gynaecological and obstetric fields we have as objectives in this manuscript to contribute: (i) to the divulgation of the knowledge of human malaria in a general context; (ii) to emphasize the gynaecological and obstetric effects of malaria in the human population.  In support of these objectives we present:

In article [2] we emphasized “uncomplicated malaria entails a series of recurring episodes of chills, intense fever, and sweating and often includes other symptoms such as headache, malaise, fatigue, body aches, nauseas, and vomiting. In some cases, and especially in groups, such as children and pregnant women, the disease can progress to “severe malaria,” including complications, such as cerebral malaria/coma, seizures, severe anaemia, respiratory distress, kidney and liver failure, cardiovascular collapse, and shock”.

This article [3] states that “if a woman gets malaria while pregnant, she and her baby have an increased risk of developing serious complications such as: (1) premature birth – birth before 37 weeks of pregnancy: (i) low birth weight; (ii) restricted growth of the baby in the womb; (2) stillbirth; (3) miscarriage – death of the mother.

Conclusion

It was here demonstrated that malaria infection can be one cause of human infertility, and of strong negatives effects on pregnant women and their babies. We hope that within a short period of time malaria is combated of sustained form in the world and that it is irradiated soon based, principally, in the   initiative of the WHO, Known as the E-2020 initiative and malaria elimination [4].

Keywords

Malaria; Anopheles; pregnancy; gynecology; obstetric; vector-borne diseases.

References

  1. White NJ (2008) Plasmodium knowlesi: the fifth human malaria parasite. Clin Infect Dis. 2008 Jan 15; 46: 172–3.
  2. Marrelli MT, Brotto M (2016) The effect of malaria and anti-malarial drugs on skeletal and cardiac muscles. Malaria Journal 15: 524,
  3. https://www.nhs.uk/conditions/malaria/complications/
  4. Q&A on the E-2020 initiative and malaria elimination – WHO (3 July 2019).

Microscopic Adenomyosis

DOI: 10.31038/IGOJ.2019241

Commentary

Endometriosis is a frequent, chronic inflammatory estrogen-dependent gynecological disease characterized by the presence of extrauterine endometrial tissue, that affects up to 10% of all reproductive-aged women. The incidence increases to 30–50% in women with chronic pelvic pain and infertility [1, 2]. Most common sites of the ectopic endometrial-like tissue are the pelvic peritoneum and ovaries, but they can be found also under the peritoneal surface, where endometriosis is strongly associated with pelvic pain symptoms [3]. This disease has a noteworthy morbidity, with harmful effect upon women’s social working, personal life, and relations with physicians [4]. Notwithstanding, the pathogenesis, as well as the diagnosis and therapy for endometriosis are still not perfectly delineated [5]. Recently, our group and others have generated convincing experimental data suggesting that perturbation of the fine-tuning of the female genital system development during a critical window of time in fetal life as the pathogenetic event prompting to the progression of endometriosis later in life [6–12].

The lack of knowledge about this disease justifies the fact that, to date, endometriosis is an incredibly under-diagnosed and under-treated disease, with an excessively long-time interval between the commencement of the symptoms and conclusive diagnosis of 8–12 years [1]. This is due to the fact that most of the symptoms are non-specific and there are no non-invasive diagnostic investigations able to reach a definitive diagnosis [13]. The definite diagnosis of endometriosis can be obtained only by histological examination of the ectopic tissue implants collected by invasive surgical or exploratory procedures [1].

The histologic diagnosis of endometriosis is, usually, quite simple and is based essentially on the recognition of both endometriosic glands and stroma, or at least by one of these two elements [1]. The histological appearance of these elements is straightforward; nevertheless, immunohistochemical staining for cytokeratin markers and for CD10 can aid in identification of glands and stroma in doubtful cases [14]. The different histopathological aspects of endometriosis are well known and have been described in detail in an elegant work of Clement some years ago [14]. Even though the histological diagnosis of endometriosis is relatively easy, also for pathologists who are not experts in this pathology, it has been reported that approximately only 50% of biopsy specimens from areas suggestive of endometriosis at laparoscopic examination have been proven microscopically to be endometriosis. Since the definitive diagnosis of this disease is based on histological examination, it is important for the correct management of the patients, to avoid false negative results at histology.

This phenomenon is particularly true in the case of adenomyosis, a condition of endometriosis in which the endometrial glands are embedded into the myometrium of the uterus [15]. Based on the Sampson’s theory, endometriosis and adenomyosis have been considered for a long time two different clinical entities and it took approximately 80 years to put forward a new theory reunifying their pathogenesis [16]. Indeed, adenomyosis is still considered today an ‘elusive’ or ‘enigmatic’ disease because of the struggle in diagnosis, and of the indefinite and vague pattern of symptoms which may accompany it. Nevertheless, the frequent association of adenomyosis with other pelvic pathologies is a further aspect which complicates the understanding of related symptoms [17]. Finally, since the moderate to severe degrees of adenomyosis can be accurately diagnosed preoperatively by good-quality ultrasound or magnetic resonance imaging, it would be desirable in the near future to correlate symptomatology with specific findings on imaging and with pathological data.

In our experience it has happened more than once to review cases, reported as negative for adenomyosis, which showed the presence of microscopic adenomyosis foci that had escaped the observation of the pathologist. As an example, in Figure 1 we show a case of multiple microscopic adenomyosis in the posterior wall of the uterus of patients with endometriosis. Indeed, ultrasound analysis had shown alterations suggestive of adenomyosis of the posterior uterine wall, but the histological analysis of the tissue taken was negative. A careful analysis of the histological preparation, however, showed the presence of microscopic endometriotic glands. Immunohistochemical analysis with cytokeratin antibodies confirmed the epithelial nature of these structures. In Figure 2 we show another case of microscopic adenomyosis, in which two small glandular structures were found in the wall of the uterus, as clearly demonstrated by immunohistochemical analysis for cytokeratin. Interestingly, analysis by CD10 clearly showed that in microscopic adenomyosis the stromal component is absent.

IGOJ-19-Alfonso Baldi_f1

Figure 1. A case of microscopic adenomyosis in the posterior wall of the uterus is depicted. In this case a multifocal microscopic adenomyosis with several very small glands was evidenced

A) Histological appearance of the multifocal adenomyosis (Hematoxylin and Eosin; original magnification X20)

B) Immunohistochemical staining for pan-cytokeratin (ABC; original magnification X10)

C) Higher magnification of figure 1B (ABC; original magnification X20)

IGOJ-19-Alfonso Baldi_f2

Figure 2. A different case of microscopic adenomyosis in the posterior wall of the uterus is shown. In this case a single small glandular structure was found

A) A small glandular structure evidenced by the immunohistochemical staining for pan-cytokeratin (ABC; original magnification X10)

B) Higher magnification of figure 1° (ABC; original magnification X20)

C) The microscopic adenomyosis does not include stroma, as demonstrated by the negative stainining for CD10 (ABC; original magnification X20)

Currently, by means of ultrasound and magnetic resonance imaging analyses, is possible to define for adenomyosis a spectrum of lesions, ranging from increased thickness of the junctional zone to evident adenomyosis and adenomyomas, which in turn can be sub classified [18]. Moreover, it is commonly accepted by the scientific community that adenomyosis is a progressive disease that changes in appearance during the reproductive years. Therefore, it has been recognized the need of a consensus classification of uterine adenomyosis [18].

Based on our experience, microscopic adenomyosis could be considered the earliest form of adenomyosis and should enter the consensus classification of adenomyosis. Furthermore, in the light of this observation, we claim that such an initial state of adenomyosis is a source of symptomatology, thus explaining the presence, as often happens, of patients with negative diagnostic tests but with symptomatology in place, for which even doubts are often raised about the presence of this pathology. Microscopic adenomyosis also provides a rational basis for the occurrence that surgical interventions often do not resolve the symptoms of chronic pelvic pain. Nevertheless, the histological features of microscopic adenomyosis give us clues to the developmental dynamics of endometriosis and adenomyosis. The prevalent glandular-epithelial composition in microscopic adenomyosis may lead to the hypothesis that the role of the stromal component becomes fundamental in a successive phase, providing an essential support to the glandular structures by virtue of its sensitivity to the higher estrogenic growth input with respect to the epithelial component [19]. Finally, we also noted that the greater is tthe multifocal representation of the glands present, the greater is the symptomatic component of pelvic pain.

In conclusion, we propose to consider microscopic adenomyosis as a specific clinical entity and to include it in the classification of uterine adenomyosis Careful histological analysis and, in doubtful cases, the use of immunohistochemistry should always be performed, to eventually confirm the presence of microscopic glands in patients with clinical and instrumental signs suggestive for adenomyosis. This would be very important to reduce the delay in the diagnosis of this clinical entity, which is still high today and causes significant problems for both patients and physicians.

References

  1. Bulun SE (2009) Endometriosis. N Engl J Med 360: 268–279.
  2. Signorile PG, Campioni M, Vincenzi B, D’Avino A, Baldi A (2009) Rectovaginal septum endometriosis: an immunohistochemical analysis of 62 cases. In Vivo 23: 459–464.
  3. Baldi A, Campioni M, Signorile PG(2008) Endometriosis: pathogenesis, diagnosis, therapy and association with cancer. Oncol Rep 19: 843–846.
  4. Fuldeore M, Chwalisz K, Marx S, Wu N, Boulanger L, et al. (2001) Surgical procedures and their cost estimates among women with newly diagnosed endometriosis: a US database study. J Med Econ 14: 115–123.
  5. Benagiano G, Brosens I (2006) History of adenomyosis. Best Pract Res Clin Obstet Gynaecol 20: 449–463.
  6. Signorile PG, Baldi F, Bussani R, D’Armiento M, De Falco M, Baldi A (2009) Ectopic endometrium in human fetuses is a common event and sustains the theory of mullerianosis in the pathogenesis of endometriosis, a disease that predisposes to cancer. J Exp Clin Cancer Res 9: 28–49.
  7. Signorile PG, Baldi A (2010) Endometriosis: new concepts in the pathogenesis. Int J Biochem Cell Biol 42: 778–780.
  8. Signorile PG, Spugnini EP, Mita L, Mellone P, D’Avino A, et al. (2010) Pre-natal exposure of mice to bisphenol A elicits an endometriosis-like phenotype in female offspring. Gen Comp Endocrinol 168: 318–325.
  9. Signorile PG, Baldi F, Bussani R, D’Armiento M, De Falco M, et al. (2010) New evidence of the presence of endometriosis in the human fetus. Reprod Biomed Online 21: 142–147.
  10. Signorile PG, Baldi F, Bussani R, Viceconte R, Bulzomi P, et al. (2012) Embryologic origin of endometriosis: analysis of 101 human female fetuses. J Cell Physiol 227: 1653–1656.
  11. Bouquet de Jolinière J, Ayoubi JM, Lesec G, Validire P, Goguin A, et al. (2012) Identification of displaced endometrial glands and embryonic duct remnants in female fetal reproductive tract: possible pathogenetic role in endometriotic and pelvic neoplastic processes. Front Physiol 3: 444.
  12. Crispi S, Piccolo MT, D’Avino A, Donizetti A, Viceconte R, et al. (2013) Transcriptional profiling of endometriosis tissues identifies genes related to organogenesis defects. J Cell Physiol 228: 1927–1934.
  13. Ballard KD, Lowton K, Wright JT (2006) What’s the delay? A qualitative study of women’s experience of reaching a diagnosis of endometriosis. Fertil Steril 85: 1296–1301.
  14. Clement PB (2007) The pathology of endometriosis: a survey of the many faces of a common disease emphasizing diagnostic pitfalls and unusual and newly appreciated aspects. Adv Anat Pathol 14: 241–260.
  15. Thylan S Adenomyosis (1995) an ignored uterine disease. Nurse Pract 20: 8–9.
  16. Benagiano G, Brosens I, Carrara S. Adenomyosis (2009) new knowledge is generating new treatment strategies. Womens Health (Lond) 5: 297–311.
  17. Peric H, Fraser IS (2006) The symptomatology of adenomyosis. Best Pract Res Clin Obstet Gynaecol 20: 547–555.
  18. Gordts S, Brosens JJ, Fusi L, Benagiano G, Brosens I (2008) Uterine adenomyosis: a need for uniform terminology and consensus classification. Reprod Biomed Online 17: 244–248.
  19. Dyson MT, Kakinuma T, Pavone ME, Monsivais D, Navarro A, et al. (2015) Aberrant expression and localization of deoxyribonucleic acid methyltransferase 3B in endometriotic stromal cells. Fertil Steril 104: 953–963.

Post-Traumatic Stress Disorder: Diagnosis and Management

DOI: 10.31038/IJOT.2019253

 

Approximately one in three people in the UK report exposure to a significant traumatic event during the course of their life [1]. Traumatic events can include serious accidents or illness, physical or sexual assault, and neglect. This exposure rate is likely to be considerably higher for those working in trauma-prone occupations such as the military, emergency services, and in less developed countries where traumatic events are more commonplace [2]. Following exposure to a traumatic event, many individuals will experience a degree of short-term distress; however, the majority will recover in time without the need for formal psychological treatment. In a minority of cases, traumatic experiences can lead to psychological injuries which may manifest as adjustment disorders, Post-Traumatic Stress Disorder (PTSD) or depression. In particular, the development of PTSD can have a profoundly negative impact on one’s quality of life, with symptoms potentially affecting one’s relationships with others, workplace performance, sleeping patterns and daily functioning. PTSD can also have adverse consequences for physical health, with a recent meta-analysis finding PTSD to be significantly associated with musculoskeletal pain, cardio-respiratory symptoms, and gastrointestinal health [3].

Diagnosing PTSD

To meet criteria for a diagnosis of PTSD, the individual is required to have been exposed to ‘actual or threatened death, serious injury or sexual violence’ [4] either through direct contact, witnessing, or by indirectly learning that a very close family member/friend has been exposed to a violent or accidental trauma; or from an accumulation of direct/indirect exposure to aversive details of traumatic event(s) – usually through the course of professional duties (e.g. personnel working with child abuse cases, journalists reporting on violent criminal proceedings) [4]. The Diagnostic and Statistical Manual (DSM-5) details four core symptom clusters (B-E in Table 1) that must be present in order to make a diagnosis of PTSD:

These symptoms must have been experienced for one month or more to meet diagnostic criteria [4]. Up until 2018 there were few differences between the classification of PTSD as described by the DSM and ICD classification systems. However, in 2018, the ICD-11 recognised both PTSD and Complex PTSD (CPTSD) as stress disorders [5]. CPTSD can develop in a subset of individuals who are either particularly vulnerable or where trauma exposure is often prolonged or recurrent, from which escape is difficult or not possible (e.g. experiences of torture, slavery, childhood sexual/physical abuse) [5]. For a diagnosis of CPTSD to be made, an individual must first meet the ICD-11 diagnostic requirements for PTSD and then three additional symptom clusters related to a Disturbance of in Self-Organisation (DSO).

Table 1. DSM-5 PTSD Diagnostic Criteria

Criterion A

Traumatic stressor

Criterion B

Intrusive re-experiencing of the event (such as traumatic nightmares or flashbacks)

Criterion C

Avoidance of reminders of the traumatic event

Criterion D

Alterations in arousal and reactivity (such as hypervigilance, exaggerated startle response, or irritability)

Criterion E

Negative alterations in mood and cognitions (such as persistent negative affect or self-perception, or amnesia for key parts of the trauma not caused by alcohol, head injury and/or drugs)3

Table 2. ICD-11 Complex PTSD Criteria

1. Meets diagnostic requirements for PTSD;

2. Problems in affect regulation;

3. Beliefs about oneself as diminished, defeated or worthless, accompanied by feelings of shame, guilt or failure related to the traumatic event;

4. Difficulties in sustaining relationships and in feeling close to others.

By definition, a diagnosis of PTSD denotes that an individual is experiencing significant functional impairment which can extend to their personal, family, social, educational, occupational or other important areas of functioning. Symptoms of posttraumatic stress in the absence of such impairment does not constitute a diagnosis of PTSD, although may warrant other diagnostic labels, such as a trauma-related adjustment disorder.

Prevalence and Risk Factors for PTSD

Recent estimates have found the one-month prevalence of PTSD in the general UK population is 4.4% [1] with overall prevalence rates being similar between adult men and women. However, young women (16–24 years) have been found to be more likely to meet PTSD criteria (12.6% compared with 3.6% of men of the same age), although this effect declines with age [1]. Rates of PTSD also differ considerably between occupational groups, with prevalence rates of up to 20% of ambulance workers, up to 20% of war reporters, and between 7–30% of combat troops [6,7].

IJOT 19 - 128_Neil Greenberg_F1

Figure 1. Flow chart for PTSD treatment. NICE 2018

While anyone can develop PTSD after a traumatic event, incidence increases with trauma severity. Other risk factors for PTSD include exposure to previous trauma, psychiatric disorder history, lower educational attainment, appraisals of the work in operational theatre as being above an individual’s trade or experience, and low unit/organisation morale or poor social support [8,9]. PTSD is also highly comorbid with other mental health disorders, with comorbidity rates often greater than 80%. The most common comorbid conditions are depression, anxiety, and substance misuse [8].

PTSD Treatment

Formal therapeutic intervention is often unnecessary in the first month following trauma exposure; in fact, evidence suggests that the early provision of psychological debriefing or trauma-counselling is potentially harmful as it may increase the likelihood of longer-term mental disorders (National Institute For Health And Care Excellence [NICE], [10]). Instead, having social support and a temporary reduction in exposure to stressors facilitates recovery in most cases. NICE guidelines advocate ‘active monitoring’ of distressed trauma-exposed individuals in the first month post-incident [10].

Evidence shows that therapies that involve an element of talking about the traumatic experiences tend to have better outcomes than supportive counselling or by managing symptoms with psychiatric medication alone [10]. Several specialist trauma-focused psychological interventions have been developed to effectively address PTSD, including exposure therapy, Trauma Focused Cognitive Behaviour Therapy (TF-CBT) and Eye Movement Desensitisation and Reprocessing (EMDR). TF-CBT has been found to be effective for improving PTSD symptoms following exposure to a variety of trauma types, including sexual assault, childhood abuse and combat trauma. EMDR is also a mainstream PTSD treatment although not recommended for war-related PTSD. Both treatments are generally delivered as 8 to 12 weekly sessions. NICE guidelines currently endorse TF-CBT for individuals who present with PTSD one to three months post-trauma. For individuals whose PTSD symptoms have been present for longer than three months, TF-CBT should also be offered but it is likely they will require additional sessions [10].

Medication for PTSD is not recommended as a routine first-line treatment strategy, although it can often be complimentary in treating symptoms and comorbid depression, or severe hyperarousal. NICE guidelines advise that Selective Serotonin Reuptake Inhibitor (SSRI), such as sertraline, or venlafaxine is considered for adults with a diagnosis of PTSD if the patient has a preference for drug treatment [10].

Role Of Healthcare Professionals

During the course of clinical practice, healthcare professionals may encounter patients who have been exposed to a range of traumas, including providing physical care for those who have been physically injured in traumatic events. The NICE guidelines recommend healthcare professionals ask questions about trauma exposure – providing the patient with examples of potential traumatic events. Questions should also include whether the patient has experienced specific symptoms (e.g. avoidance, dissociation, nightmares, hyperarousal, etc.) [10].

While some healthcare professionals may feel ill-equipped to ask about trauma exposure or have concerns that such questions may provoke further patient distress, they should not avoid doing so. Being able to discuss a traumatic experience can be cathartic and, if distress is evident, then a referral for a formal assessment can be arranged. Asking about trauma exposure, and associated symptoms, sensitively as well as the impact that the trauma has had on a patient’s daily functioning, should be within the capability of all healthcare professionals. For example, an orthopaedic surgeon should consider and feel confident asking such questions when treating a patient who has suffered life changing injuries following a road traffic accident.

 Individuals who are identified as having PTSD should be provided with appropriate guidance about the condition (e.g. the Royal College of Psychiatrist PTSD information leaflet) and advised to attend a formal mental health assessment, particularly where there are concerns about the chronicity or severity of symptoms. Information should also be provided to the family members or caregivers about supporting their loved one following a traumatic event. Families/caregivers may also help encourage individuals to attend formal assessments which is important as avoidance is a key PTSD symptom and unfortunately most people in the UK who have PTSD do not receive any professional intervention [1].

Particularly following workplace trauma, there is good evidence that peer-support programmes can be especially effective in facilitating recovery [11]. In a UK military context, investing in efforts to improve informal and formal support for trauma-exposed troops has been found to be successful, both in protecting the mental health of personnel and in reducing the stigma around mental health problems within the military [6]. Thus, it may be beneficial for healthcare professionals to be provided with information regarding local organisations and peer-support groups, such as MIND, Big White Wall or the Veterans Gateway for military veterans.

It should be noted that while the media often portrays certain groups, such as emergency service personnel or military veterans, as being particularly reluctant to seek help for mental health difficulties, a failure to seek formal support for trauma-related psychological problems reflects a societal issue rather than the mindset of specific professions [1]. Therefore, it is recommended that healthcare professionals encourage patients and colleagues with chronic and impairing trauma-related symptoms to access social support or formal treatment. A further consideration is that treatment options for more complex presentations of PTSD, while available on the NHS can be challenging to access depending on where someone lives.

As with any mental health problem, the family members of an individual suffering with PTSD can also be vicariously affected. Research has shown that spouses and children of individuals with PTSD can experience significant mental health difficulties themselves, including secondary PTSD symptoms and emotional dysregulation problems [12, 14]. The provision of psychoeducation to families, an assessment of family member’s needs, as well as emotional support may be beneficial to augment familial coping.

Summary

In summary, while most people who experience traumatic events may have short-term distress, only a minority will develop PTSD. PTSD can have a debilitating effect on not only their lives, but the lives of their families, colleagues and friends. In the initial period after a traumatic event, the majority of people benefit from access to social support and a temporary reduction in stress. For the minority who do develop PTSD, there are evidence-based talking trauma-therapies which can improve functioning and psychological wellbeing. While it is ideal to access such treatments within months of a trauma, so that the negative impact on one’s life is kept to a minimum, treatment can be effective even after a delay – allowing those with PTSD to continue to lead fulfilling lives once again, even if the full resolution of symptoms is not possible in some cases.

References

  1. Fear NT, Bridges S, Hatch S, Hawkins V, Wessely S (2016) Posttraumatic stress disorder. In: McManus S, Bebbington P, Jenkins R BT (eds), editor. Mental health and wellbeing in England: Adult Psychiatric Morbidity Survey.  Leeds: NHS Digital, Leeds, England Pg No: 991.
  2. Perkonigg A, Kessler RC, Storz S, Wittchen H-U (2016) Traumatic events and post-traumatic stress disorder in the community: prevalence,risk factors and comorbidity. Acta Psychiatr Scand 101: 46–59.
  3. Pacella ML, Hruska B, Delahanty DL (2013) The physical health consequences of PTSD and PTSD symptoms: A meta-analytic review. J Anxiety Disord 27: 33–46.
  4. American Psychiatric A. (2013) Diagnostic and Statistical Manual of Mental Disorders (DSM-5®) [Internet]. American Psychiatric Pub Pg No: 991.
  5. World Health Organisation. (2018) ICD-11 – Mortality and Morbidity Statistics.
  6. Greenberg N, Jones E, Jones N, Fear NT, Wessely S (2010) The injured mind in the UK Armed Forces. Philos Trans R Soc B Biol Sci 366: 1562.
  7. McFarlane AC, Williamson P, Barton CA (2009) The impact of traumatic stressors in civilian occupational settings. J Public Health Policy 30: 311–27.
  8. Bisson J, Ehlers A, Matthews R, Pilling S, Richards D, et al. (2007) Psychological treatments for chronic post-traumatic stress disorder. Br J Psychiatry 198: 97–104.
  9. Iversen AC, Greenberg N (2009) Mental health of regular and reserve military veterans. Adv Psychiatr Treat 15: 2.
  10. National Institute for Health and Care Excellence N. Post-traumatic stress disorder: management (2018).
  11. Brooks S, Amlôt R, Rubin GJ, Greenberg N (2018) Psychological resilience and post-traumatic growth in disaster-exposed organisations: overview of the literature. J R Army Med Corps Pg No: 1–5.
  12. Leen-Feldner EW, Feldner MT, Knapp A, Bunaciu L, Blumenthal H (2013) Offspring psychological and biological correlates of parental posttraumatic stress: Review of the literature and research agenda. Clin Psychol Rev 33: 1106–33.
  13. Diehle J, Brooks SK, Greenberg N (2016) Veterans are not the only ones suffering from posttraumatic stress symptoms: what do we know about dependents’ secondary traumatic stress? Soc Psychiatry Psychiatr Epidemiol  Pg No: 1–10.
  14. Williamson V, Stevelink SAM, Da Silva E, Fear NT (2018) A systematic review of wellbeing in children: a comparison of military and civilian families. Child Adolesc Psychiatry Ment Health Pg No: 12: 46.

Hemiarthroplasty or Total Hip Replacement for intracapsular Hip Fractures? A Dilemma in Trauma Surgery

DOI: 10.31038/IJOT.2019252

 

Hip fractures in the elderly are a common and devastating injury, placing a considerable burden on healthcare systems around the world. In the UK there are over 70,000 hip fractures annually, costing around £2billion [1].Given the ever-ageing population, future estimates suggest that that over 6 million hip fractures/year will occur worldwide by 2050 [2].Mortality and morbidity following these injuries remains high, in England with a 30-day mortality of 8.5% [3].

Displaced intracapsular fractures are at risk of non-union and avascular necrosis, and treatment in the form of a hemiarthroplasty or Total Hip Replacement (THR) is recommended [4]. The choice between these remains controversial [5], with potential benefits and risks associated with each. Traditionally, hemiarthroplasty has been the mainstay of treatment as it is less complex and thus quicker surgery, with reduced bleeding and complications [6]. However, some studies suggest improved function following a THR [7], and surgeons worry about long-term acetabular wear from hemiarthroplasties, and the subsequent need for conversion to a THR [8].

Population studies in the USA [9], Finland [10] and South Korea [11] have shown trends demonstrating increasing utilisation of THR in these patients for this fracture. In the UK, in 2011, the National Institute of Health and Clinical Excellence (NICE) produced guidance on when a THR should be offered to hip fracture patients [12]. They recommended offering a THR to patients who: (a) could walk independently, (b) were not cognitively impaired, and (c) were medically fit for anaesthesia and the procedure [12]. By 2017 the first of these criteria was revised to patients who are able to walk independently outdoors with no more than the use of a stick [13]. Despite this, in the UK compliance to NICE guidelines remains poor, with one study, published in 2016, of over 100,000 patients showing less than a third of eligible patients received a THR [4].

Several potential reasons exist regarding this low compliance. First, these cases require an experienced arthroplasty surgeon [4], not always feasible especially in smaller centres, contributing to a delay in treatment, and increased morbidity and mortality. In our unit, we have shown in an as of yet unpublished retrospective study of patients who all met the NICE criteria that those receiving a THR waited considerably longer than hemiarthroplasty patients (3.7 days versus 1 day respectively, P < 0.05). Second, it has been acknowledged the precise indications for THRs in hip fractures are not well defined [4] with some authors feeling the current NICE criteria are too inclusive [14], particularly in patients with significant co-morbidities (the most common reason hemiarthroplasties were chosen over THRs) [14]. This was supported as hemiarthroplasty patients were older, and had significantly increased 1 year mortality, suggesting greater frailty in these patients, despite all being eligible for THRs [14]. In our local study we too found those undergoing a hemiarthroplasty were older (mean age 83 vs 73 years) and had an increased 1 year mortality (18.2% vs 8.3%), despite all patients meeting NICE criteria.Indeed, one population-based study on THR usage in hip fractures showed NICE guidance was less likely to be followed in older patients, and those with worse cognition, ASA grade and ambulatory status [4].

The literature on the outcome of THRs compared to hemiarthroplasties is also equivocal, with a variety of studies supporting each approach. One recent meta-analysis of prospective studies supported THR [15], demonstrating improvements in function as measured by the Harris Hip Score (HHS) and Quality of Life (SF-36), reduced re-operation rates [15]and beyond 4 years no difference in dislocation rates [15].However, the authors acknowledge inconsistencies in trial design [15], and it is worth noting the implants and selection criteria varied widely between studies. Interestingly, the authors also conclude those patients older than 80 years, or those with a short life expectancy, both THR and hemiarthroplasty are both reasonable interventions [15].

Another retrospective UK study using over 7,000 matched patients, on a national database, showed no difference in revision rates between implants [16]. This finding was reinforced by another study showing the conversion rate of hemiarthroplasties to THRs for acetabular wear was low, particularly in older patients (1.4% in patients older than 75 years) [8].

The short to medium term dislocation rate in THR patients has been shown to be significantly higher than for hemiarthroplasty patients [16,17]. A randomised prospective study assessing long-term outcomes at 12 years found no difference in complication or re-operation rates between groups, and actually demonstrated equivalent function as measured using the modified HHS [5]. This study concluded by advising cemented hemiarthroplasty in hip fracture patients aged greater than 70 years, in the absence of radiological evidence of joint degeneration [5].

In conclusion, THR surgery was once famously described as the ‘operation of the century [18], helping to revolutionise the management of patients crippled with osteoarthritis [18]. Its role in these patients is not disputed. However its role in trauma remains controversial [5]. We feel THR can also achieve excellent results in hip fracture patients, but at present the ideal patient, and precise indications are not well defined [4]. Furthermore emergency surgery is usually defined ‘as life or limb saving’ which should be as simple and expeditious as possible, particularly in the elderly and infirm. The decision for THR or hemiarthroplasty is multi-factorial and includes surgical experience, facilities and importantly patient morbidity/ASA, frailty and age. It is our opinion that current NICE guidelines are too inclusive. Until more conclusive data shows otherwise, surgical decision-making should remain at the discretion of the attending surgical team and local circumstances.

References

  1. Royal College of Physicians (2014)  National Hip Fracture Database annual report London
  2. Dhanwal DK, Dennison EM, Harvey NC (2011) Epidemiology of hip fracture: worldwide geographic variation. Indian J Orthop 15–22.
  3. Neuburger J, Currie C, Wakeman R (2015) The impact of a national clinician-led audit initiative on care and mortality after hip fracture in England: an external evaluation using time trends in non-audit data. Med Care 686–91.
  4. Perry DC, Metcalfe D, Griffin XL (2016) Inequalities in use of total hip arthroplasty for hip fracture: population based study. BMJ
  5. Tol CJM, van den Bekerom MPJ, Sieneveldt (2017) Hemiarthroplasty or total hip arthroplasty for the treatment of a displaced intracapsular fracture in active elderly patients. 12-year follows up of randomised trial. Bone Joint J 250–54
  6. Keating J, Grant A, Masson M (2005) Displaced intracapsular hip fractures in fir, older people: a randomised comparison of reduction and fixation, bipolar hemiarthroplasty and total hip arthroplasty. Health Technol Assess1–65.
  7. Avery PP, Baker RP, Walton MJ (2011) Total hip replacement and hemiarthroplasty in mobile, independent patients with a displaced intracapsular fracture of the femoral neck: a seven-to ten-year follow-up report of a prospective randomised controlled trial. J Bone Joint Surg Br 93: 1045–8.
  8. Grosso MJ, Danoff JR, Murtagh JS (2017) Hemiarthroplasty for displaced femoral neck fractures in the elderly has a low conversion rate. J Arthroplasty 32: 150–54.
  9. Bishop J, Yang A, Githens M (2016) Evaluation of contemporary trends in femoral neck fracture management reveals discrepancies in treatment. Geriatr Orthop Surg Rehabil 7:135–41.
  10. Hongisto MT, Pihlajamaki H, Niemi S (2014) Surgical procedures in femoral neck fractures in Finland: a nationwide study between1998 and 2011. Int Orthop 38: 1685–1690.
  11. Lee YK, Ha YC, Park C (2013). Trends of surgical treatment in femoral neck fracture: a nationwide study based on claim registry. J Arthroplasty 28: 1839–1841.
  12. National Institute for Health and Clinical Excellence (2011). NICE clinical guideline 124. Hip fracture: the management of hip fracture in adults. NICE
  13. National Institute for Health and Clinical Excellence (2017) NICE clinical guideline 124 (addendum).  Hip fracture: the management of hip fracture in adults. NICE
  14. Walker LC, Lee LH, Webb M (2016) Provision of total hip replacement for displaced intracapsular hip fracture and the outcomes: an audit of local practice based on NICE guidelines. Hip Int 26: 153–7.
  15. Lewis DP, Waever D, Thorninger R (2019) Hemiarthroplasty vs Total hip arthroplasty for the management of displaced neck of femur fractures: a systematic review and meta-analysis. J Arthroplasty; 34:1837–1843.
  16. Jameson SS, Lees D, James P (2013) Cemented hemiarthroplasty or hip replacement for intracapsular neck of femur fracture? A comparison of 7732 matched patients using national data. Injury 44: 1940–44.
  17. Van den Bekerom MP, Hilverdink EF, Sierevelt IN (2010) A comparison of hemiarthroplasty with total hip replacement for displaced intracapsular fracture of the femoral neck: a randomised controlled multicentre trial in patients aged 70 years and over. J Bone Joint Surg Br 92B: 1422–8.
  18. Learmonth ID, Young C, Rorabeck C (2007) The operation of the century: total hip replacement. Lancet 370: 1508–1519.

A Case of Necrotizing Fasitis in a Patient Injecting Pomegranate Juice into Her Thigh

DOI: 10.31038/IJOT.2019245

Introduction

Necrotizing Fasciitis (NF) is a disease characterized by rapidly spreading necrosis of soft tissues and fascia, which can lead to rapid death if not treated appropriately [1, 2]. Etiology includes surgical incision, insect sting, incision, abrasion, contusion, injection, skin ulcer, perirectal abscess, incarcerated hernia, burn, splinter ingestion, birth and penetrating trauma [3]. In 70% of NF cases, the agent can be isolated in wound culture; 20% for blood culture. Gram-positive bacteria are in the foreground and 70–90% of the cases are polymicrobial [4].

Early diagnosis, broad-spectrum antibiotic therapy and surgical debridement are essential. Despite treatment, 30% of the patients die [5]. In this case report, we wanted to report the treatment of a NF patient who injected pomegranate juice with the thought of storing energy in his right thigh and right elbow of a drug addict, homeless and foreign national (Ukrainian Citizen) with serial debridement and skin grafting.

Case

A 36-year-old male patient of unknown nationality who was abandoned to the emergency department was consulted with the preliminary diagnosis of abscess in the extremities. In the examination of the patient; swelling, redness and ballotmaning of the right hip compared to the left hip. He also had an infected discharge wound on the anterior face of the right elbow. The patient’s general condition was fond, orientated, cooperative. Glaskow coma score was 14 and neurological examination was normal. In laboratory tests CRP: 326 mg / l, WBC: 23.19 10³ / mcl, Hb: 12.9 g / dl, Na: 134mmol / L, creatinine: 0.8 mg / dl (70.7 mmol / L), glucose: 122mg / dl ( 11.3 mmol / L). In the presented case, the LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score was calculated to be 8 during the first application (Table I).

On radiological examinations, X-ray radiography showed gas shadows compatible with NF in the right thigh region (Figure 1). MRI; Fluid collections were observed starting from the right gluteal region and extending to the proximal of the thigh, the largest of which was approximately 6.5 × 4 cm lateral to the proximal section of the thigh (abscess?) (Figure 2). Superficial tissue USG; There were diffuse edema findings in the right arm and a 45mm collection-abscess.

Table 1. Laboratory Risk Indicators for Necrotizing Fasciitis (LRINEC).

Value

LRINEC score

Values of the case

C-reaktif protein (mg/L)

<150

>150

0

4

326

White blood cell count (cell/mm3)

<150

15–25

>25

0

1

2

23

Hemoglobin level (g/dL)

>13.50

11–135

<11

0

1

2

12.9

Sodium level (mmol/L)

≥135

<135

0

2

134

Creatinine level (mg/dL)

≤1.6

>1.6

0

2

0.8

Olucoie dOzeyi (mg/dL)

≤180

>180

0

1

122

Emergency debridement was planned in the emergency department within 6–8 hours due to worsening of the general condition, high infection parameters, hemodynamic instability, change in consciousness and septic shock. Radical debridement, abscess drainage, abundant washing was performed and culture samples were taken in the operating room conditions (Figure 3,4). He was transferred to the postoperative intensive care unit. Subsequently, serial debridement was performed 5 times at 48 hour intervals. At each debridement stage, the patient was evaluated for amputation. In this process, he was treated by infectious diseases according to the patient’s clinic, blood parameters and culture results. Two weeks later, when he did not need intensive care, he was transferred to the orthopedic clinic. The patient underwent re-debridement and a Vacuum-Assisted Wound Care System (VAC) was applied.

In the wound culture sample, Escherichia Coli was produced. Methicillin-resistant Staphylococcus epidermidis was isolated in blood cultures. One week later, Acinetobacter Baumannii was isolate in blood culture too. 2 weeks after admission CRP was 141 mg / l, WBC was 11.99 × 10³ / mcl, Hb value was 8.3 g / dl, Na: 137 mmol / L, Kr: 0.44 mg / dl (38.5 mmol / L), glucose: 77mg / dl (7.13 mmol / L). LRINEC score was 2.

As a result of the complete disappearance of infection findings 1.5 months later, wound areas were closed with skin grafts taken from the opposite thigh (Figure 5,6). After the lack of medical needs of the patient for lack permission to remain in Turkey it was deported by mobile discharged. The whole process took 2.5 months.

IJOT 19 - 125_Ertürk C_F1

Figure 1.F X-ray image of gas shadows on patient’s right thigh

IJOT 19 - 125_Ertürk C_F2

Figure 2. MRI image of abscess on the right thigh of the patient

IJOT 19 - 125_Ertürk C_F3

Figure 3. Drained abscess on the right elbow of the patient

IJOT 19 - 125_Ertürk C_F4

Figure 4. Perop right thigh drainage image

IJOT 19 - 125_Ertürk C_F5

Figure 5. Right thigh image after serial debridements

IJOT 19 - 125_Ertürk C_F6

Figure 6. Appearance of the thigh after grafting

Discussion

Although rare, every surgeon treats at least one NF case throughout his life [6]. Rapidly spreading necrosis can cause systemic sepsis, toxic shock syndrome and multiorgan failure [7]. The patient was in septic shock when we operated.

LRINEC risk score was accepted as high risk with 8 points at the first admission [8]. Early, aggressive treatment is required and necrotizing fasciitis is an surgical emergency [9]. The patient should be evaluated as a whole and the decision of amputation should be reviewed at every stage. The recommended intravenous antibiotic therapy depends on the etiological factors; however, clindamycin, penicillin and third-generation cephalosporins can be started empirically [10].

Delay of the first debridement may increase mortality up to 71% [11]. Although we considered the possibility of amputation after each debridement in our case, we have always emphasized limb sparing surgery [3]. In addition, the length of hospital stay in NF cases brings a significant financial burden [12].

As a result; Many problems were dealt with during the diagnosis, treatment and discharge phase of the patient, who was a foreign national, had no relatives and no insurance. We tried to apply the early diagnosis, antibiotic therapy and surgical debridement approaches, which are the principle of NF, appropriately. After serial debridement, wound and blood culture, antibiotic therapy and VAC treatment, skin grafting was applied to the wounds. With the treatment principles, the patient’s survival and return to life were achieved.

References

  1. Trent JT, Kirsner RS (2002) Diagnosing necrotizing fasciitis. Adv Skin Wound Care 15: 135–8.
  2. File TM Jr, Tan JS, DiPersio JR (1998) Group A streptococcal necrotizing fasciitis. Diagnosing and treating the “flesh-eating bacteria syndrome”. Cleve Clin J Med 65: 241–9.
  3. Carter PS, Banwell PE (2004) Necrotising fasciitis: a new management algorithm based on clinical classification. Int Wound J 1: 189–98.
  4. Shaikh N, El-Menyar A, Mudali IN, Tabeb A, Al-Thani H (2015) Clinical presentations and outcomes of necrotizing fasciitis in males and females over a 13-year period. Ann Med Surg (Lond) 4: 355–60.
  5. Sun X, Xie T (2015) Management of Necrotizing Fasciitis and Its Surgical Aspects. Int J Low Extrem Wounds. 14: 328–34.
  6. Naqvi GA, Malik SA, Jan W (2009) Necrotizing fasciitis of the lower extremity: a case report and current concept of diagnosis and management. Scand J Trauma Resusc Emerg Med Pg No: 17–28.
  7. Fichev G, Kostov V, Marina M, Tzankova M (1997) Fornier’s gangrene: a clinical and bacteriological study. Anaerobe 3: 195–7.
  8. Wong CH, Khin LW, Heng KS, Tan KC, Low CO (2004) The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med 32: 1535–41.
  9. McDonald LS, Shupe PG, Raiszadeh K, Singh A (2014) Misdiagnosed pneumothorax interpreted as NF of the chest wall: case report of potentially prevntable death. Patient Saf Surg 8: 20.
  10. Shaikh N, El-Menyar A, Mudali IN, Tabeb A, Al-Thani H (2015) Clinical presentations and outcomes of necrotizing fasciitis in males and females over a 13-year period. Ann Med Surg (Lond) 4: 355–60.
  11. Kuncir EJ, TillouA, Hill CR, Ptrone P, Kimbrell B, Asencio JA (2003) Necrotizing soft tissue infections. Emerg Med Clin North Am 21: 1075–87.
  12. Widjaja AB, Tran A, Cleland H, Leung M, Millar I (2005) The hospital costs of treating necrotizing fasciitis. ANZ J Surg 75: 1059–64.

Promoting Medication-Adherence by Uncovering Patient’s Mindsets and Adjusting Clinician-Patient Communication to Mindsets: A Mind Genomics Cartography

DOI: 10.31038/JCRM.2019243

Abstract

We present a new approach to understanding how patients want doctors to communicate to them. The approach uses Mind Genomics, an emerging science in experimental psychology, which looks at the way people make decisions about the everyday. Respondents in an experiment evaluated different combinations of messages (elements) in vignettes. The results suggest three minds (privacy-oriented; doctor oriented; control-oriented), requiring three different types of messages. These mind-sets also pay attention to the messages in different ways, as shown by the pattern of their response times. We present a PVI (personal viewpoint identifier), which in six questions can suggest the mind-set to which a new person might belong.

Introduction

Patient self-management programs are the aim of health systems and public health policy makers. The main goal of health systems is to improve clinical outcomes of patients by engaging them to adhere to medications, to adopt a healthy lifestyle and to properly manage their illnesses. Patient adherence is defined as the degree to which patients follow physician’s guidelines and recommendations. Patient non-adherence has been a challenge for clinicians with evidence indicating that 25% to 50% of patients are non-adherent [1–4]. Furthermore, patients suffering a more severe illness in serious diseases were surprisingly less adherent [5]. Consequently, across illnesses non-adherence results in comorbidities, re-admissions to hospitals, in lower quality of life and in economic burdens for public health systems. Adherence to guidelines and medications was found to promote illness-self management (e.g., appointments, screening, exercise, and diet).Adherence is affected by: clinician-patient relationship, the illness itself, the treatment, patient characteristics and socioeconomic factors [6].

Patients expect their physicians to inspire them through communication leading to patient trust which is strongly related to medication-adherence[7–9]. Physician-patient communication was found to enhance patient adherence to decrease re-admissions [10,11]. To promote adherence patients need to understand the illness, the risks it entails and the treatment benefits [11]. Clinician-patient communication is an essential in adherence promotion [11–14]. Moreover, the odds of patient adherence are 2.16 times higher if a clinician communicates effectively [2,5,15].

Communication entails support, empathy and compassion leveraging collaborative patient-physician decision-making [9,12]. Whereas ‘content communication’ focuses on clinical aspects of the disease (e.g., the illness, the treatment regimens), ‘process communication’ focuses on psychosocial aspects (motivation, drivers, life–meaning, gathering information about the patient and environment, understanding how to remove barriers to adherence and identifying steps in the change process towards adherence.

‘Process communication has been report found to effectively raise patient-adherence [2,10,16–19]. Furthermore, patients who perceived their clinicians as their partners to the change process demonstrated a 19% higher medication-adherence. Furthermore, training physicians on ‘process communication’ improved patient-adherence by 12% [5,18,19]Essentials of behavioral research: methods and data analysis McGraw-Hill; 2007.

Despite evidence those clinicians’ skills of process communication are central to patient-adherence; clinicians mostly use content communication and have difficulties crossing this chasm [20]. Several factors underlie the challenge of crossing this chasm. First, there is a lack of sufficient training on psychosocial communication during and after medical school [20]. Second, there is a low prioritization of such skills in training programs [21]. Third, there is a lack of incentives for physicians to participate in such training [22]. Finally, there are misconceptions among physicians who perceive psychosocial communication as time consuming [23] when in fact it requires shorter, more effective time [18].

Previous studies suggest that interventions to improve psychosocial communication among clinicians should focus on a variety of aspects, not just one. These aspects are, respectively, verbal and nonverbal communication, affective communication, psychosocial communication and task-oriented behavior that create opportunities for active patient involvement throughout the change process towards patient-adherence [24]. Previous studies indicate that in order to reduce barriers which stand in the way of optimal health outcomes, communication is to be personalized enabling clinicians to understand what is most relevant for each particular patient and tailor the messages accordingly [4].

But what do we know about the mind of the patient? How can we find out what the patient feels to be important? What does the patient feel is relevant and irrelevant for her or him? In response to existent discourse in the literature, in 2011we conducted an internet experiment using Mind-Genomics to investigate combinations of messages on ‘living with the regimen’ (Moskowitz, unpublished observations).We identified three mind-sets. This study extends the 2011 study looking more closely at messages about how people feel about themselves in terms of how the doctor communicates with them. Our objective is to identify participants by psychographic mindsets so clinicians may quickly identify the belonging of each patient to a mindset and use tailored effective communication congruent to that mindset-segment in the context of medication adherence.

Method

Mind Genomics works in a Socratic fashion, first identifying a topic, then requiring the researcher to ask four questions, and finally requiring the researcher to provide four separate answers to each question. Inspired by existing literature and research instruments, we shaped questions which ‘tell a story’ [25–30]. Once the questions are asked, the answers are quickly provided. Asking the questions forces the researcher to think critically. Table 1 shows the four questions and the four answers to each question. The series of questions probe the way the person feels about information. The ‘story’ underlying the four questions is not sequential, but rather topic, as if an interview were being conducted with a person to under how the person feels about giving and receiving information about his or her own health status.

Table 1. Raw material comprising four questions, and four answers to each question

Question A: How would you like your doctor to discuss your health with you?

A1

Doctor talks to me, face to face… not just those phone calls with clinical message

A2

Doctor explains to me WHY this medicine, and what should I DO

A3

My friends explain this stuff to me… I’m more comfortable with them

A4

Doctor guides me to the Internet sites… so I CAN TAKE CONTROL

Question B: What honestly is your relationship with your health?

B1

I’m pretty private about my health… no one’s business

B2

I don’t feel like going to the doctor… even for the most severe symptoms… I can take care of it

B3

When it comes to illness, I’m on Google, so I really become an expert

B4

I’m nervous about health – but really want to be healthy to see my kids, grandkids, or even relatives and friends in the years to come

Question C: How do you interact with your family about your health?

C1

My family is always there to listen, and support me… I like that

C2

My family and others butt-in to my health… I want my privacy

C3

I really am happy when someone takes control, and tells me what to take, and schedules my meds for me

C4

I’m pretty private… my health meds are my business… and maybe the doctor’s, but that’s all

Question D: Do friends and family play an important role in your life?

D1

My family means the world to me

D2

I reach out to talk to friends about my health and illness

D3

I reserve my friends for non-medical talks, like politics, or people

D4

My friends really are there to listen to me about my medical experience – sometimes I feel I’m wearing out my welcome

Procedure

Vignettes: The test stimuli for Mind Genomics comprise easy-to-read vignettes, containing 2–4 answers or elements, at most one answer or element from each question. The vignettes are created according to an experimental design, which prescribes the specific combination. Each respondent evaluated 24 vignettes created according to the same basic design, with the specific combinations changing in a deliberate fashion according to a permutation scheme [31]. Thus, the entire experiment covered 24×100 or 2400 vignettes, most of which differed from each other.

It is important to note that the Mind Genomics approach to understanding is similar metaphorically to the MRI machine, which takes many different ‘pictures’ of the underlying tissue, each picture from a different angle and vantage point. Afterwards, a computer program combines these different views into a single 3-D image of the underlying tissue. Each individual picture may have error, but the entire pattern becomes clear once these individual pictures are combined. In a like fashion, Mind Genomics gets the response to many different vignettes, and then synthesizes the overall pattern. Each individual observation is ‘noisy’ with a base size of ‘1’ but the pattern is not as noisy.

The approach of Mind-Genomics covers a wide range of alternative clinical and psychosocial communication concepts, each with elements revealing response patterns by using various permutations of the same stimuli, responses to different combinations of the answers of elements, in order to obtain a stable estimate of the underlying pattern Conventional science attempts to minimize the error around each observation through replication of the same stimulus (average to increase precision)or through reduction of extraneous factors which could increase the error variability (suppressing noise to increase precision).

The respondents were selected at random from a pool of 20+ million respondents in the United States, with approximately equal distribution of age and gender. The respondents were part of the panel provided by the strategic partner of Mind Genomics, Luc.id, Inc. Respondents were compensated by Luc.id.

Each respondent who participated clicked on an embedded link in the email invitation and was taken to a first slide which oriented the respondent. The respondent was told to consider the entire vignette, the combination of elements (answers) as a ‘whole’ and to rate it on the scale below. The questions were never shown to the respondent. Only the answers were shown; the questions served simply as a way to elicit the set of appropriate answers that would be shown to the respondent in the vignette.

Imagine if these qualities were reflected on a magnet. How does this capture your thoughts?

1= Not at all like me. If this is a magnet, it just won’t work for me

5= Very much like me. This magnet will really help me

A surface analysis of the responses – distribution and means

Most surveys work with the responses to single questions and compute the mean of the responses. Mind Genomics proceeds by experimentation, presenting the respondent with combinations of answers or elements, and obtains their rating. The actual ratings themselves pertain to different test stimuli. Furthermore, an inspection of the different patterns across gender and ages fails to give us any insight into the mind of the respondent with respect to feelings about discussing one’s own state of health and receptivity to health information. The means across key subgroups (Table 2) provides little insight, other than perhaps that older respondents had a longer response time, on average, than did younger respondents. A deeper analysis is necessary to understanding the meaning of the data, not just the surface morphology of the response patterns.

Table 2. Mean ratings on the 5-point rating scale, by total panel, gender, and ages

 

5- Point RATING

Binary TOP2 (Works YES)

Binary BOT2 (Works No)

Response Time

Total

3.2

42

31

5.0

Male

3.1

42

32

4.7

Female

3.2

42

31

5.4

Age 18–30

3.2

38

30

4.3

Age 31–49

3.4

53

27

4.5

Age 50–64

2.9

34

37

6.1

Transforming the data in preparation for regression modeling

In consumer research an oft-heard complaint from managers who use the data is ‘what does the rating point mean?’ In consumer research, the values of the scales are not necessarily easy to understand. That is, for researchers and respondents it seems easy to use the 5-point or 9-point or even a 100-point like rt scale. It may take a bit of use for a respondent, but sooner or later, usually sooner, the respondent falls into a pattern and intuitively senses that ‘this vignette is a 3 or a 4.’

One strategy commonly used, and adopted here, divides the scale into two regions, typically the high region (scale points 4–5) to denote a positive feeling about the vignette, and the remaining low region (scale points 1–3) to denote a negative feeling. We are interested in both sides of the scale, however, specifically what ‘works’ and what ‘don’t work’. Thus, we divide the scale twice, first into the top part and then second into the bottom part:

Works YES – Ratings 1–3 transformed to 0, ratings 4–5 transformed to 100

Works NO – Ratings 1–2 transformed to 100, ratings 3–5 transformed to 0.

The transformation removes some of the granular information but makes the results easy to understand. Managers who work with the data understand in an intuitive sense, because the information is presented in a all-or-none fashion.

Regression Modeling

The experimental design makes it straightforward to apply OLS (ordinary least-squares) regression to the raw data, after transformation. The data matrix comprises 16 independent variables, the elements, coded as 1 when present in the vignette, and coded as 0 when absent from the vignette. The matrix comprises three dependent variables, the binary transformation for Works YES (4–5 coded as 100, 1–3 coded as 0), the binary transformation for Works NO (1–2 coded as 100, 3–5 coded as 0), and the response time in seconds with the resolution to the nearest tenth of second. The response time is defined as the recorded time between the appearance of the vignette on the respondent’s screen and the time to assign a rating, which the respondent did by pressing a key.

Results –Total Panel

OLS regression generates an equation relating the presence/absence of the 16 answers or elements to the response. Table 2 shows the parameters of the three equations, one each for the positive Works YES, the negative Works NO, and the response time.

The additive constant (Works YES, Works NO) shows the estimated percent of the time the answer would be ‘Works YES or Works NO, in the absence of any elements. The additive constant represents a baseline, but not an actual situation because all vignettes by design comprised 2–4 elements or answers.’

The coefficient for each element shows the additive percent of the responses that would be expected to shift from ‘not Works YES’ to ‘Works Yes’ (or from ‘not Works NO’ to ‘Works NO), when the element is incorporated into a vignette. Statistical analyses as well as previous research by author Moskowitz suggest a standard error of approximately 4 for the coefficient, making values of 6–7 begin to reach statistical significance.

The results lead to some immediate and easy interpretation because the test elements are cognitively rich. We don’t have to stand back and search for a pattern in the way we do when we are looking at the pattern described by set of otherwise mute measures. Rather, we can understand the nature of a pattern simply by looking at the elements which score well, with high coefficients for the two binary scales (Works YES, Works NO) and long response times.

What ‘works’ for the respondent (Adherence promotion): The additive constant is 43, meaning that in the absence of anything else, we expect about 43% of the responses to be 4–5 for ‘Works YES.’ This means that if we were to ask a person whether giving and receiving medical information from various sources in general ‘works for that person’ almost 50% of the time we would get a positive answer. The strongest performers comprise a mix of statements about getting information directly from the doctor (Doctor talks to me, face to face… not just those phone calls with clinical message) as well as emotional messages (I’m nervous about health – but really want to be healthy to see my kids, grandkids, or even relatives and friends in the years to come and My family means the world to me.)

What doesn’t ‘work’ for the respondent (Adherence prevention): The additive constant is 30; meaning about 30% of the time we will get responses that say ‘doesn’t work for me’ the key message which resonates in a negative way is ‘I don’t feel like going to the doctor… even for the most severe symptoms… I can take care of it. This is not an easy negative to resolve.

Response time: The model for response time does not have an additive constant. The rationale is that without any elements, there is no response at all.

Studies on health drive respondents to pay a great deal of attention to the vignettes. Table 2 shows that the average for the total panel is approximately 5 seconds for a vignette. The response time, when deconstructed into the contributions of the different messages, show that there is a range of response times, all of which are high compared to the response times from previous studies. In this study the estimated response times for the individual answers or elements vary from a high of 1.8 seconds to a low of 1.1 seconds. We end up with these long response times when we deal with topics relevant to the respondent, issues which engage and make the respondent think. In contrast, when we deal with less relevant topics, e.g., studies about products such as foods, we see far shorter response times. It might be that the messages are easier with foods, being tag lines and short descriptions. Whatever the reason for the difference, the response times are far longer here.

The longer response times are those which ‘engage.’ They may be positive or negative, but they ‘engage’ the respondent, holding the attention. The most engaging elements are these below, describing who the person is, and perhaps forcing the respondent to compare him or herself. One can sense that each of these statements is a ‘conversation opener.’

When it comes to illness, I’m on Google, so I really become an expert I’m pretty private about my health… no one’s business

I really am happy when someone takes control, and tells me what to take, and schedules my meds for me

My family and others butt-in to my health… I want my privacy

I’m nervous about health – but really want to be healthy to see my kids, grandkids, or even relatives and friends in the years to come

I don’t feel like going to the doctor… even for the most severe symptoms… I can take care of it

In contrast, the least engaging elements are those of practice, with a sense that there is no conversation to be started

Doctor explains to me WHY this medicine, and what should I DO

I reach out to talk to friends about my health and illness

Table 3. Coefficients relating the presence/absence of the 16 answers (elements) to the binary transformed ratings, and to response time. The table is sorted by Works YES

Works YES

Works NO

Resp Time

Additive constant

43

30

A1

Doctor talks to me, face to face… not just those phone calls with clinical message

7

-8

1.3

B4

I’m nervous about health – but really want to be healthy to see my kids, grandkids, or even relatives and friends in the years to come

6

-1

1.6

D1

My family means the world to me

6

-6

1.3

A2

Doctor explains to me WHY this medicine, and what should I DO

5

-5

1.2

D4

My friends really are there to listen to me about my medical experience – sometimes I feel I’m wearing out my welcome

1

2

1.5

C4

I’m pretty private… my health meds are my business… and maybe the doctor’s, but that’s all

1

0

1.4

A4

Doctor guides me to the Internet sites… so I CAN TAKE CONTROL

0

-3

1.4

B3

When it comes to illness, I’m on Google, so I really become an expert

-1

3

1.8

C1

My family is always there to listen, and support me… I like that

-1

0

1.5

B1

I’m pretty private about my health… no one’s business

-2

5

1.7

A3

My friends explain this stuff to me… I’m more comfortable with them

-2

0

1.3

D3

I reserve my friends for non-medical talks, like politics, or people

-3

1

1.4

D2

I reach out to talk to friends about my health and illness

-3

-2

1.1

C3

I really am happy when someone takes control, and tells me what to take, and schedules my meds for me

-5

6

1.7

C2

My family and others butt-in to my health… I want my privacy

-6

4

1.7

B2

I don’t feel like going to the doctor… even for the most severe symptoms… I can take care of it

-7

11

1.6

Scenario Analysis: Uncovering Pair-Wise Interactions among Answers/Elements: The messages that we encounter in the environment comprise combinations of ideas, rather than single ideas in ‘splendid isolation.’ We know that in the world of food, the taste of a food is determine by the interplay of ingredients, and that experimental design of ingredients can help us understand the nature of that interplay, also called ‘pairwise interaction’. In consumer research with ideas, we may test single messages (promise testing), or test combinations of messages in a final format (concept testing), but rarely do we search for significant pairwise interactions in the world of ideas. There are so-called ‘creative’ in the advertising agency who may be aware that some ideas ‘synergize’ when in pairs, but this knowledge is specific, experienced-based, and hard to create in a systematic fashion on a go-forward basis.

A key benefit of the Mind Genomics approach is the ability to cover many combinations of ideas in the vignettes, all combinations prescribed by a basic experimental design which is permuted (Gofman & Moskowitz, 2010.) Adhering to the experimental design forces the research to work with a wide number of different combinations. In fact, among the 2400 vignettes created for this study, most are unique. Within the 2400 combinations, specific pairs of messages appear several times. It is this property that the various pairs of messages appear several times across the permutations which makes it possible to hold one the options of one question constant a specific option (e.g., one of the options for Question A: How would you like your doctor to discuss your health with you?), and then assess how the vignettes perform when that specific option is held constant.

Table 4 presents the scenario analysis for the positive responses (Works YES), and Table 5 presents the scenario analysis for the negative response (Works NO). The analysis works in a straightforward manner, following these steps:

Table 4. Scenario analysis, revealing pairwise Interactions to drive perceived positive responses, ‘Works YES’

Element held constant in the vignette

A0

A1

 A2

A3

A4

Top 2 – Works YES (Positive Outcome)

 

 

No element from question A

Doctor talks to me, face to face… not just those phone calls with clinical message

Doctor explains to me WHY this medicine, and what should I DO

My friends explain this stuff to me… I’m more comfortable with them

Doctor guides me to the Internet sites… so I CAN TAKE CONTROL

A0

A1

A2

A3

A4

Additive Constant

28

53

50

50

34

B4

I’m nervous about health – but really want to be healthy to see my kids, grandkids, or even relatives and friends in the years to come

15

10

1

-5

17

D1

My family means the world to me

14

-8

3

16

11

C4

I’m pretty private… my health meds are my business… and maybe the doctor’s, but that’s all

11

-5

1

-9

11

B1

I’m pretty private about my health… no one’s business

7

7

-4

-17

-2

D2

I reach out to talk to friends about my health and illness

6

-9

-4

-7

3

B3

When it comes to illness, I’m on Google, so I really become an expert

5

12

0

-8

-6

C2

My family and others butt-in to my health… I want my privacy

2

-15

-10

-1

-5

B2

I don’t feel like going to the doctor… even for the most severe symptoms… I can take care of it

1

1

-5

-24

-6

C1

My family is always there to listen, and support me… I like that

1

-5

1

-1

-3

C3

I really am happy when someone takes control, and tells me what to take, and schedules my meds for me

0

-7

-3

-3

-7

D4

My friends really are there to listen to me about my medical experience – sometimes I feel I’m wearing out my welcome

-2

-2

-1

-2

17

D3

I reserve my friends for non-medical talks, like politics, or people

-6

-8

-3

5

4

Table 5. Scenario analysis, revealing pairwise Interactions to drive perceived negative responses, ‘Works NO’

Bot 2 – Works NO (Negative Outcome)

No element from question A

Doctor talks to me, face to face… not just those phone calls with clinical message

Doctor explains to me WHY this medicine, and what should I DO

My friends explain this stuff to me… I’m more comfortable with them

Doctor guides me to the Internet sites… so I CAN TAKE CONTROL

A0

A1

A2

A3

A4

Additive Constant

37

21

23

27

31

C3

I really am happy when someone takes control, and tells me what to take, and schedules my meds for me

9

1

7

8

7

C2

My family and others butt-in to my health… I want my privacy

6

4

4

5

5

C1

My family is always there to listen, and support me… I like that

5

3

0

-2

-1

B2

I don’t feel like going to the doctor… even for the most severe symptoms… I can take care of it

4

7

7

16

13

D3

I reserve my friends for non-medical talks, like politics, or people

2

2

6

-4

-6

D4

My friends really are there to listen to me about my medical experience – sometimes I feel I’m wearing out my welcome

2

8

2

-2

-4

C4

I’m pretty private… my health meds are my business… and maybe the doctor’s, but that’s all

0

0

1

7

-8

B1

I’m pretty private about my health… no one’s business

-5

0

7

12

9

D1

My family means the world to me

-6

2

-2

-17

-9

D2

I reach out to talk to friends about my health and illness

-8

8

0

-3

-8

B3

When it comes to illness, I’m on Google, so I really become an expert

-9

-3

4

9

8

B4

I’m nervous about health – but really want to be healthy to see my kids, grandkids, or even relatives and friends in the years to come

-11

-6

-2

8

-6

  1. Identify the variable to be held constant. In our study, this is Question A: How would you like your doctor to discuss your health with you?
  2. In our 4×4 design (four questions, four answers per question), Question A has five alternatives, comprising the four answers and the ‘no answer’ option wherein Question A does not contribute to a vignette.
  3. We sort the full set of 2400 records, one record per vignette per respondent, based upon the specific answer. This step ‘stratifies’ the database, into five strata, one stratum for each answer. One stratum comprises those vignettes without an answer to Question A.
  4. We then run the OLS regression on each stratum, but do not use A1-A4 as independent variables since they are held constant in a stratum.
  5. The coefficients tell us the contribution of each element to WORKS YES, for a specific answer.
  6. Thus, when we have A0, we deal with no answer from Question A.
  7. The additive constant is 28, meaning that for these vignettes we are likely to get only 28% positive response (works for ME, rating 4–5).The additive constant, 28, is probably the lowest level we will reach in basic response.
  8. Three very strong performing answers emerge. These are likely to lead to strong positive feelings, even starting from the low baseline of 28

    I’m nervous about health – but really want to be healthy to see my kids, grandkids, or even relatives and friends in the years to come

    My family means the world to me

    I’m pretty private… my health meds are my business… and maybe the doctor’s, but that’s all

  9. Now let us move to the strongest performing answer, A1: Doctor talks to me, face to face… not just those phone calls with clinical message. When this answer is the keystone of the vignette, the additive constant jumps up to 53. That means that in the absence of anything else, just knowing that message increases the frequency of positive answers 4–5 on the 5-point scale, namely Works YES
  10. When we combine this strong basic idea presented in A1 with the two answers or elements below, we end up with an additional 10% to 12% positive responses.

    When it comes to illness, I’m on Google, so I really become an expert

    I’m nervous about health – but really want to be healthy to see my kids, grandkids, or even relatives and friends in the years to come

  11. When we run the scenario analysis looking at the Works NO (a negative outcome), we see that without any element from question A, the additive constant is highest (37), and then decreases as the doctor becomes increasing involved. When the doctor talks with the respondent, the additive constant is lowest (A1 = face to face = additive constant 21; A2 = doctor explains = additive constant 23.)

    The most negative elements come from interactions where either the friends explain the medical material, or the doctor guides the respondent to the internet, allowing the respondent to take control.

  12. Response time. We can perform the same scenario analysis. This time, however, we eliminate the condition where an answer to A does not appear (A0). Table 6 shows the dramatic effects of interaction. The response time changes depending upon the specific element from question A about how the respondent wants to get information. A dramatic example comes from answer A1 (doctor talks to me face to face…). When A1 is paired with B1 (I’m pretty private about my health … no one’s business) the response time for element B1 is 3.0 seconds. When A4 (Doctor guides me to the internet sites…) is paired with B1, the response time for element B1 is just about half, 1.4 seconds.

Table 6. Scenario analysis, revealing pairwise Interactions to drive response time

 

Doctor talks to me, face to face… not just those phone calls with clinical message

Doctor explains to me WHY this medicine, and what should I DO

My friends explain this stuff to me… I’m more comfortable with them

Doctor guides me to the Internet sites… so I CAN TAKE CONTROL

A1

A2

A3

A4

B1

I’m pretty private about my health… no one’s business

3.0

2.1

2.2

1.4

B3

When it comes to illness, I’m on Google, so I really become an expert

2.6

2.3

2.2

1.8

C1

My family is always there to listen, and support me… I like that

2.5

1.4

1.6

2.3

B4

I’m nervous about health – but really want to be healthy to see my kids, grandkids, or even relatives and friends in the years to come

2.3

2.0

2.3

1.3

D4

My friends really are there to listen to me about my medical experience – sometimes I feel I’m wearing out my welcome

1.2

2.4

2.0

2.5

B2

I don’t feel like going to the doctor… even for the most severe symptoms… I can take care of it

2.2

1.8

2.5

1.4

C3

I really am happy when someone takes control, and tells me what to take, and schedules my meds for me

2.0

1.6

2.0

2.6

C2

My family and others butt-into my health… I want my privacy

1.5

1.8

1.7

2.4

D3

I reserve my friends for non-medical talks, like politics, or people

1.7

2.0

2.0

2.2

C4

I’m pretty private… my health meds are my business… and maybe the doctor’s, but that’s all

1.8

1.5

1.8

2.0

D1

My family means the world to me

1.7

1.9

1.6

2.0

D2

I reach out to talk to friends about my health and illness

1.2

2.0

1.7

1.8

It is clear from Table 6 that there is cognitive processing occurring, with the data suggesting that mutually contradictory elements, in terms of implications, the respond processes the information, attempting to resolve these contradictory elements.

Responses from Key Subgroups

Positive Outcome (Works YES): Table 7 presents the performance of the elements by key subgroups, comprising gender, age, and stated concern about their health. In the interest of easing the inspection, we present only those elements which score well with at least one of the key subgroups.

Table 7. Performance of the answers/elements by key subgroup for the criterion ofWorks YES. Only strong performing elements for at least one subgroup are shown

Top 2 – Works YES

Male

Female

Age 18–30

Age 31–49

FW 50+

Don’t think

Healthy

Concerned

Additive Constant

45

42

29

58

33

26

48

43

A1

Doctor talks to me, face to face… not just those phone calls with clinical message

5

10

7

4

12

17

-3

16

A2

Doctor explains to me WHY this medicine, and what should I DO

9

1

2

7

4

6

2

7

A3

My friends explain this stuff to me… I’m more comfortable with them

0

-3

1

3

-6

17

-6

0

A4

Doctor guides me to the Internet sites… so I CAN TAKE CONTROL

2

-2

3

4

-2

22

-4

2

B3

When it comes to illness, I’m on Google, so I really become an expert

-4

3

2

-2

-1

9

-1

-2

B4

I’m nervous about health – but really want to be healthy to see my kids, grandkids, or even relatives and friends in the years to come

3

8

10

1

8

-1

1

11

D1

My family means the world to me

4

8

3

-1

16

1

4

8

D4

My friends really are there to listen to me about my medical experience – sometimes I feel I’m wearing out my welcome

4

-2

13

-4

-2

5

0

1

The key differences emerge from the additive constants and a few elements, only. Most respondents are positive. The least positives are two groups; those age 18–30 (additive constant = 29) and those age 50+ (additive constant 33) and those not concerned with their health (additive constant = 26). The only groups which surprises are those age 50+.

Looking across subgroups, we find two messages which appear to do well on a consistent basis

Doctor talks to me, face to face… not just those phone calls with clinical message

But really want to be healthy to see my kids, grandkids, or even relatives and friends in the years to come

Looking down, within a subgroup, we find some patterns which strongly resonate, and are meaningful when we think about the needs and wants of the subgroup.

Those age 50+

I’m nervous about health – but really want to be healthy to see my kids, grandkids, or even relatives and friends in the years to come

My family means the world to me

Those who classify themselves as not concerned

Doctor talks to me, face to face… not just those phone calls with clinical message

My friends explain this stuff to me… I’m more comfortable with them

Doctor guides me to the Internet sites… so I CAN TAKE CONTROL

When it comes to illness, I’m on Google, so I really become an expert

When we perform the same analysis, this time for the lower part of the scale (Works NO), where ratings 1–2 were assigned 100, and ratings 3–5 were assigned 0, we find a different pattern. We again present only those elements which score strongly among at least one of the subgroups.

When we look at the key subgroups, we find that most of the groups begin with a low additive constant, which means that they feel these messages will not do any harm. The two groups which surprise are those who are age 50+ (additive constant = 44) and those who say that they are concerned about their health (additive constant = 48.)The likelihood is probably their fear that the ‘wrong’ thing could exacerbate a problem. In contrast those who are age 31–49 show a very low additive constant (12), as do those who classify themselves as health (additive constant = 18).

The additive constant provides only part of the story. Some of the elements drive a perception of poor outcomes, especially those who call themselves healthy. A pleasant surprise is that the elements which these self-described healthy respondents feel to lead to a bad outcome are those which talk about avoiding the medical establishment. That is, those who consider themselves health are already aware of good practices, and react negatively to poor practices, as shown by the high coefficients for this reversed scale.

I don’t feel like going to the doctor… even for the most severe symptoms… I can take care of it

I’m pretty private about my health… no one’s business

My friends explain this stuff to me… I’m more comfortable with them

Emergent Mind Sets Showing Different Patterns of What is Important

One of the ingoing premises of Mind Genomics is that within any topic area where people make decisions or have points of view there exist mind-sets, groups of ideas which ‘go together.’ Mind Genomics posits that at any specific time, a given individual will have only one of the several possible mind-sets, although over time, e.g., years or due to some unforeseen circumstance, one’s mind-set will change.

The metaphor for a mind-set it a mental genome. There is no limit to the number of such mental genomes, at least in terms of defining them by experiments. Virtually every topic can be broken down into smaller and smaller topics, and studied, from the very general to the most granular. In that respect, Mind Genomics differs from its namesake, Biological Genomics, which posits that there are a limited number of possible genes. In Mind Genomics, each topic area comprises a limited number of mind genomes, but there are uncountable topics.

The notion of mind-sets in the population, these so-called mind genomes, opens a variety of vistas. From the vantage point of psychology, the mind-genomes present the opportunity to study individual differences in the world of the everyday, and to systematize these differences, perhaps even finding ‘supersets’ of mind genomes which go across many different types of behavior. From the vantage point of biology, discovering mind-genomes holds the possibility of ‘correlating’ mind-genomes with actual genomes. And finally, from the vantage point of economics and commerce, discovering the pattern of a person’s mind genomes leads to better customer experience, and perhaps more responsiveness to suggestions about lifestyle modifications in the search for better health. The last is the focus of this study, the search for how to best communicate to people.

The process of uncovering mind genomes or mind-sets is empirical, modeling the relation between elements and responses (our Works YES model), clustering the respondents on the basis of the pattern of their coefficients, and finally extracting clusters which are few in number (parsimony), and which are coherent and meaningful, telling a ‘simple story’ (interpretability).Clustering has become a standard method in exploratory data analysis (e.g., Dubes & Jain, 1980.)

The approach to creating these mind-sets has already been documented extensively in [25–30]. It is vital to keep in mind that modeling and clustering is virtually automatic and intellectual agnostic. It takes a researcher to determine whether the clusters, the so-called mind-sets, really make sense when interpreted. There is no way for the clustering algorithm to easily interpret the meaning of the clusters other than perhaps doing a word count. The involvement of the research is vital, albeit not particularly taxing. The computer program does all the work.

The clustering based on the positive outcome models (Works YES) suggest three interpretable mind-sets, shown in Table 9 fop the positive outcome, Works YES, and in Table 10 for the negative outcome, Works NO. The names for the mind-sets were selected on the basis the elements which scored highest for the Works YES models. The mind-sets make sense (privacy seeker; doctor focus; control focus) for both the positive and the negative models (Works YES, Works NO), respectively. The clustering also parallels preliminary results from the aforementioned study run eight years before, in 2011(Moskowitz, unpublished), which suggested three similar three mind-sets of this type. It is important to note that these mind-sets are not ‘set in stone,’ but rather represent interpretable areas in what is more likely a continuum of preferences.

Table 9. Performance of the answers/elements by three emergent mind-sets for the criterion of Works YES

 Positive Outcome – Works YES
(Basis for the mind-set segmentation)

MS3 Privacy-seeker

MS2 Doctor focus

MS1 Control focus

Additive constant

45

50

34

C4

I’m pretty private… my health meds are my business… and maybe the doctor’s, but that’s all

15

-1

-13

A1

Doctor talks to me, face to face… not just those phone calls with clinical message

-7

15

16

A2

Doctor explains to me WHY this medicine, and what should I DO

-11

11

16

A4

Doctor guides me to the Internet sites… so I CAN TAKE CONTROL

-15

11

8

D1

My family means the world to me

-5

10

15

B4

I’m nervous about health – but really want to be healthy to see my kids, grandkids, or even relatives and friends in the years to come

3

2

14

D4

My friends really are there to listen to me about my medical experience – sometimes I feel I’m wearing out my welcome

-9

5

9

D2

I reach out to talk to friends about my health and illness

-11

-3

8

B3

When it comes to illness, I’m on Google, so I really become an expert

5

-16

8

A3

My friends explain this stuff to me… I’m more comfortable with them

-16

6

7

B1

I’m pretty private about my health… no one’s business

5

-19

5

D3

I reserve my friends for non-medical talks, like politics, or people

-2

-8

3

B2

I don’t feel like going to the doctor… even for the most severe symptoms… I can take care of it

5

-23

-6

C3

I really am happy when someone takes control, and tells me what to take, and schedules my meds for me

0

-3

-12

C1

My family is always there to listen, and support me… I like that

4

7

-14

C2

My family and others butt-in to my health… I want my privacy

2

-2

-18

Table 10. Performance of the answers/elements by three emergent mind-sets for the criterion of Works NO

Negative Outcome – Works NO

MS3 Privacy-focus

MS2 Doctor focus

MS1 Control focus

Additive constant

24

34

31

A3

My friends explain this stuff to me… I’m more comfortable with them

16

-5

-11

D4

My friends really are there to listen to me about my medical experience – sometimes I feel I’m wearing out my welcome

11

-8

-1

A2

Doctor explains to me WHY this medicine, and what should I DO

10

-12

-12

A4

Doctor guides me to the Internet sites… so I CAN TAKE CONTROL

10

-9

-12

B2

I don’t feel like going to the doctor… even for the most severe symptoms… I can take care of it

8

12

13

C3

I really am happy when someone takes control, and tells me what to take, and schedules my meds for me

5

9

6

B1

I’m pretty private about my health… no one’s business

4

9

4

C4

I’m pretty private… my health meds are my business… and maybe the doctor’s, but that’s all

-9

1

9

C1

My family is always there to listen, and support me… I like that

0

-8

8

A1

Doctor talks to me, face to face… not just those phone calls with clinical message

2

-14

-12

B3

When it comes to illness, I’m on Google, so I really become an expert

5

7

-2

B4

I’m nervous about health – but really want to be healthy to see my kids, grandkids, or even relatives and friends in the years to come

-2

-1

-1

C2

My family and others butt-in to my health… I want my privacy

2

6

7

D1

My family means the world to me

-4

-8

-7

D2

I reach out to talk to friends about my health and illness

2

-2

-6

D3

I reserve my friends for non-medical talks, like politics, or people

-3

3

1

Response Time (engagement) – Key Subgroups: Table 11 shows us the differences in response time across the 16 elements. The data are repeated for the total panel, along with the estimated response times for each element by each key subgroup. The patterns differ by subgroup. Some of the key results are:

  1. Males focus for longer times about being an expert and wanting privacy.

    When it comes to illness, I’m on Google, so I really become an expert

    I’m pretty private about my health… no one’s business

  2. Females focus slight longer about most of the elements than do males. Two elements capture their attention, but do not capture the attention of males

    Doctor talks to me, face to face… not just those phone calls with clinical message

    My friends explain this stuff to me… I’m more comfortable with them

  3. The youngest respondents (age 18–30) focus on only one element

    My friends really are there to listen to me about my medical experience – sometimes I feel I’m wearing out my welcome

  4. The oldest respondents focus a lot more time than other respondents on the need for expertise and privacy

    When it comes to illness, I’m on Google, so I really become an expert

    I’m pretty private about my health… no one’s business

    My family and others butt-in to my health… I want my privacy

  5. Those who say they are not concerned focus a great deal on one element

    I don’t feel like going to the doctor… even for the most severe symptoms… I can take care of it

  6. Those who say they are healthy focus on

    When it comes to illness, I’m on Google, so I really become an expert

    I’m pretty private about my health… no one’s business

  7. Those say they are concerned about their health focus a great deal on two issues, opposites of each other

    My family and others butt-in to my health… I want my privacy

    I really am happy when someone takes control, and tells me what to take, and schedules my meds for me

  8. The privacy mind-set focuses on privacy, but also on the lack of privacy (someone else taking control). Keep in mind that this is response time, not a judgment. The respondents in this mind-set pay attention to the statement about someone else taking control, rather than just disregarding it.

    When it comes to illness, I’m on Google, so I really become an expert

    My family and others butt-in to my health… I want my privacy

    I’m pretty private about my health… no one’s business

    I really am happy when someone takes control, and tells me what to take, and schedules my meds for me

  9. The doctor mind-set actually spends more time on elements which do not agree with their mind-set and spend little time on elements dealing with the doctor. It is as if they are ‘wired’ to accept the information of the doctor but have to think about contravening data.

    My friends explain this stuff to me… I’m more comfortable with them

    When it comes to illness, I’m on Google, so I really become an expert

    My family and others butt-in to my health… I want my privacy

  10. The control mind-set focus on loss of control, again spending little time on elements which agree with their mind-setI really am happy when someone takes control, and tells me what to take, and schedules my meds for me

Table 8. Performance of the answers/elements by key subgroup for the criterion of Works NO. Only strong performing elements for at least one subgroup are shown

 

Bot 2 – Works NO

Male

Female

Age 18–30

Age 31–49

Age 50+

Don’t think

Healthy

Concerned

Additive Constant

29

30

34

12

44

32

18

38

A3

My friends explain this stuff to me… I’m more comfortable with them

2

-1

-2

2

0

-9

10

-7

B1

I’m pretty private about my health… no one’s business

4

6

2

10

2

1

12

1

B2

I don’t feel like going to the doctor… even for the most severe symptoms… I can take care of it

13

9

2

15

13

-4

14

10

B3

When it comes to illness, I’m on Google, so I really become an expert

3

4

4

7

-1

-7

8

1

B4

I’m nervous about health – but really want to be healthy to see my kids, grandkids, or even relatives and friends in the years to come

1

-3

-9

6

-4

0

9

-10

C3

I really am happy when someone takes control, and tells me what to take, and schedules my meds for me

4

9

6

6

10

-7

9

5

D1

My family means the world to me

-4

-8

-16

2

-10

10

-8

-5

D2

I reach out to talk to friends about my health and illness

-4

1

-7

1

-1

13

-1

-2

Table 11. Response times for elements, by total panel and key subgroups

 

 

total

Male

Female

A18–30

A31–49

50+

Not concerned

Healthy

Concern

Doctor focus

Control focus

B3

When it comes to illness, I’m on Google, so I really become an expert

1.8

1.7

1.9

1.4

1.6

2.1

2.2

1.9

1.6

1.9

1.6

B1

I’m pretty private about my health… no one’s business

1.7

1.7

1.7

1.5

1.3

2.2

1.6

2.0

1.5

1.8

1.5

C2

My family and others butt-in to my health… I want my privacy

1.7

1.4

2.0

1.4

1.7

2.0

1.3

1.4

2.0

1.4

1.8

C3

I really am happy when someone takes control, and tells me what to take, and schedules my meds for me

1.7

1.5

1.8

1.0

1.8

1.9

1.6

1.2

2.0

1.4

1.9

B2

I don’t feel like going to the doctor… even for the most severe symptoms… I can take care of it

1.6

1.4

1.7

1.2

1.5

1.8

2.6

1.7

1.3

1.9

1.2

B4

I’m nervous about health – but really want to be healthy to see my kids, grandkids, or even relatives and friends in the years to come

1.6

1.6

1.6

1.4

1.6

1.6

1.5

1.5

1.6

1.8

1.4

C1

My family is always there to listen, and support me… I like that

1.5

1.5

1.5

1.1

1.4

1.8

1.8

1.1

1.9

1.3

1.7

D4

My friends really are there to listen to me about my medical experience – sometimes I feel I’m wearing out my welcome

1.5

1.5

1.6

1.9

1.0

1.9

2.0

1.2

1.8

1.8

1.3

A4

Doctor guides me to the Internet sites… so I CAN TAKE CONTROL

1.4

1.2

1.6

1.1

1.3

1.7

-0.3

1.4

1.6

1.5

1.3

C4

I’m pretty private… my health meds are my business… and maybe the doctor’s, but that’s all

1.4

1.3

1.5

1.0

1.3

1.8

1.1

1.0

1.8

1.2

1.3

D3

I reserve my friends for non-medical talks, like politics, or people

1.4

1.4

1.4

1.4

1.1

1.8

1.7

1.4

1.4

1.7

1.1

A1

Doctor talks to me, face to face… not just those phone calls with clinical message

1.3

1.0

1.6

0.9

1.1

1.8

-0.2

1.3

1.5

1.3

1.4

A3

My friends explain this stuff to me… I’m more comfortable with them

1.3

1.0

1.7

1.0

1.4

1.5

0.6

1.2

1.5

2.0

1.0

D1

My family means the world to me

1.3

1.6

0.9

1.5

0.9

1.6

1.9

1.2

1.3

1.6

1.3

A2

Doctor explains to me WHY this medicine, and what should I DO

1.2

1.0

1.4

1.1

1.1

1.6

0.6

1.0

1.5

1.4

1.3

D2

I reach out to talk to friends about my health and illness

1.1

0.9

1.3

1.4

0.7

1.3

0.3

1.1

1.1

1.4

1.0

Identifying Sample Mindsets at the Clinic

The conventional wisdom in consumer research is that we can use a person’s demographics or psychographics to predict the mind-set to which the person belongs. The actual practice is to cluster people based upon their demographics, attitudes and/or behavior, arriving at a set of individuals who LOOK different by standard measures, and then to map these clusters to different ways of thinking about the same problem.

 The conventional approach occasionally works but fails to deal with the granularity of the situations having many aspects. The different aspects of a single topic, such as dealing with medical information, may generate a variety of different groups of mind-sets, depending upon the topic of medical information, whether that be simply informative, or prescriptive, and forth. Conventional research is simply too blunt an instrument to assign people to these different arrays of mind-sets, each of which emerges from different aspects of the same general problem. Once granularity becomes a factor in one’s knowledge, the standard methods no longer work, in light of the vastly increased sophistication of one’s knowledge about a topic.

An example of the difficulty of traditional methods to assign new people to the three mind-sets uncovered here can be sensed from Table 12, which shows the membership pattern in the three mind-sets by gender, by age, and by self-described concern with one’s health. The distributions are similar across the three mind-sets. One either needs much more data, from many other measured aspects of each person, or a different way to establish mind-set membership in this newly uncovered array of three mind-sets emerging from the granular topic of the way one wants to give and get medical information.

Table 12. Distribution of mind-set membership by gender, age, and self-described concern with one’s health

Privacy focus

Doctor focus

Control focus

Total

100

38

29

33

 

Male

51

18

16

17

Female

49

20

13

16

 

Age 18–30

21

11

5

5

Age w

39

14

12

13

Age 50+

37

12

11

14

Not answered

3

1

1

1

 

Healthy

44

20

12

12

Concerned

49

17

13

19

Never think about it

7

1

4

2

Discovering these three mind-sets in the population by a PVI (Personal Viewpoint Identifier)

The ideal situation in research is to discover a grouping of consumers, e.g., our three mind-sets, and then discover some easy-to-measure set of variables which, in concert, assign a person to a mind-set. With such an assignment rule it may be possible to scan a database of millions of people, and assign each person in the database to one of the empirically discovered mind-sets. That process may work, but the occasions are few and far between.

An alternative method uses the coefficients from the three mind-sets to create a typing tool, a set of questions with simple answers, so that the pattern of answers assigns a person to one of the three mind-sets. The method uses the coefficients for Works YES (Table 9), identifies the most discriminating patterns, and then simulates many thousands of data sets, perturbing each data set thousands of times. These data sets are, for each mind-set, the 16 coefficients and the additive constant. The process is a so-called Monte-Carlo simulation.

The actual PVI is available at the link below, as of this writing (summer, 2019).

http://pvi360.com/TypingToolPage.aspx?projectid=78&userid= 2018

Figure 1 shows the information collected from the respondent (classification), and Figure 2 shows the actual PVI questions. In practice they are randomized. Following the six questions, the patterns of answers to which assign a person to a mind-set, we see four additional questions that the respondent who is doing the typing can answer, to provide additional information.

Mind Genomics-026 - JCRM Journal_F1

Figure 1. The self-classification, completed at the start of the PVI

Mind Genomics-026 - JCRM Journal_F2Figure 2. The actual PVI showing the six PVI questions, and the four general questions below

Discussion and conclusions

This study identified mindsets regarding how the person would like to communicate with the physician the underlying goal being to increase adherence through proper communication. Communication messaging typically involves identifying a subgroup by common characteristics of its members and according the information to group members by these characteristics (Kreuter, Strecher& Glassman, 1999). The notion underlying this approach is that group members possess similar characteristics and, therefore, will be influenced by the same message. Similarly, in health communication, messaging may be customized to a subgroup, members of which share characteristics such as illness, health conditions and needs, etc. Individuals, however, are most persuaded by personally relevant communication and are more likely to pay attention and to process such information more thoroughly (Petty &Cacioppo, 2012).

Since fitting a message to meet personal needs of patients, rather than group criteria, is more effective for influencing attitudes and health behaviors, we suggest that to promote adherence, clinicians should tailor their messages to individuals. Sophisticated approaches to tailor communication aimed at changing complex health behaviors such as adherence, call upon clinicians to integrate detailed information into communication messages for each patient (Cantor &Kihlstrom, 2000).An advantage of such strategies for communication is that messages tailored to a patient do not need to be modified very often (Schmid, Rivers, Latimer &Salovey, 2008).

Our viewpoint enables clinicians to identify the sample mindset to which a patient in the population belongs, for a specific topic, i.e., granular. Messages about adherence and non-adherence should be congruent with those specifically strong elements for the mind-set to which the patient belongs for the particular topic. There are some messages which appear to be universal, such as the need of patients to have eye contact with the clinician. At the deeper level, the level of granular message; the data suggests three mind-sets, membership in which should be known to the physician and guide style of communication.

People belonging to the first mindset focus on privacy and expect their clinician to take control (e.g., tell me what to take, schedules my meds for me).

People belonging to the second mindset accept what the clinician advises them but spend time discussing it with other patients and enhancing their knowledge on Google. People in this mindset expect their clinician to carry a dialogue respecting the information they learned and their thoughts.

People belonging to the third mindset, need to have control. Aiming at behavioral changes and adherence promotion, clinicians might adopt communication with a tonality of process oriented, along with personal relevance for the patient.

Tailoring the message to the patient requires the clinician to assess each patient belonging to a mindset by asking the six questions according to our viewpoint identifier.

Acknowledgement

Attila Gere thanks the support of the Premium Postdoctoral Researcher Program of the Hungarian Academy of Sciences

References

  1. DiMatteo MR (2004) Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. MedicalCare 42: 200–209.
  2. Haskard-Zolnierek KB, DiMatteo MR (2009) Physician communication and patient adherence to treatment: a meta-analysis. Medical care 47: 826.
  3. Vermeire E, Hearnshaw H, Van Royen P (2001) Patient adherence to treatment: three decades of research, a comprehensive review. J Clin Pharm Ther26: 331–342.
  4. Zolnierek KB, DiMatteo MR(2009) Physician communication and patient adherence to treatment: a meta-analysis. Medical care 47: 826.]
  5. DiMatteo MR, Haskard KB, Williams SL (2007) Health beliefs, disease severity, and patient adherence: a meta-analysis. Medical Care45: 521–528.
  6. Sabate E (2003) Adherence to long-term therapies: Evidence for action. Geneva: World Health Organization.
  7. Gabay G, Moskowitz HR (2012)the algebra of health concerns: implications of consumer perception of health loss, illness and the breakdown of the health system on anxiety. International Journal of Consumer Studies36: 635–646.
  8. Gabay G (2015) Perceived control over health, communication and patient- physician trust. Patient Education and Counseling98: 1550–1557.
  9. Beck RS, Daughtridge R, Sloane PD (2002) Physician-patient communication in the primary care office: a systematic review. Journal of the American Board of Family Practice15: 25–38.
  10. Gabay G (2016) Exploring perceived control and self-rated health in re-admissions among younger adults: A retrospective Study. Patient Education and Counseling 99: 800–806.
  11. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353: 487–497.
  12. Chewning B, Sleath B (1996) Medication decision-making and management: a client-centered model. SocSci Med 42: 389–398.
  13. Squier RW (1990) A model of empathic understanding and adherence to treatment regimens in practitioner-patient relationships. SocSci Med 30: 325–339.
  14. Stewart MA (1984) what is a successful doctor-patient interview? A study of interactions and outcomes. SocSci Med 19: 67–175.
  15. DiMatteo MR, Haskard-Zolnierek KB, Martin LR (2012) Improving patient adherence: a three-factor model to guide practice. Health Psychology Review 1: 74–91.
  16. Haynes RB, Yao X, Degani A, Kripalani S, Garg A, et al.(2005) Interventions to enhance medication adherence. Cochrane Database Systematic Review 4
  17. Haynes R, Ackloo E, Sahota N, McDonald H, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database of Systematic Review 2: CD000011.
  18. Ratanawongsa N, Karter AJ, Parker MM, Lyles CR, Heisler M, et al. (2013Communication and medication refill adherence: the Diabetes Study of Northern California. JAMA internal medicine11: 173–210.
  19. Rosenthal R, Rosnow R (2007) Essentials of behavioral research: methods and data analysis. McGraw-Hill.
  20. Levinson W, Lesser CS, Epstein RM (2010) Developing physician communication skills for patient-centered care. Health affairs29: 1308–1310.
  21. Epstein RM, Street RL (2007) Patient-centered communication in cancer care: promoting healing and reducing suffering. National Cancer Institute.
  22. Brown RF, Butow PN, Dunn SM, Tattersall MH (2001) Promoting patient participation and shortening cancer consultations: a randomised trial. British Journal of Cancer 85: 1273.
  23. Tulsky JA (2005) Interventions to enhance communication among patients, providers, and families. Journal of palliative medicine 8: 95.
  24. Rao JK, Anderson LA, Inui TS (2007) Communication interventions make a difference in conversations between physicians and patients: a systematic review of the evidence. Med Care45: 340–349.
  25. Gabay G, Zemel G, Gere A, Zemel R, Papajorgji P, et al. (2018) On the threshold: What concerns healthy people about the prospect of cancer.Cancer Studies and Therapeutics Journal 3: 1–10.
  26. Gabay G, Gere A, Stanley J, Habsburg-Lothringen C, Moskowitz HR(2019) Health threats awareness – Responses to warning messages about cancer and smartphone Usage. Cancer Studies Therapy Journal4: 1–10.
  27. Gabay G, Gere A, Zemel G, Moskowitz D, Shifron R, et al. (2019) Expectations and attitudes regarding chronic pain control: An exploration using Mind Genomics. Internal Medicine Research Open Journal4: 1–10.
  28. Gabay G, Gere A, Moskowitz HR (2019) Uncovering communication messages for health promotion: The case of arthritis. Integrated Journal of Orthopedic Traumatology2: 1–13.
  29. Gabay G, Gere A, Moskowitz HR. (2019) Understanding effective web messaging – The Case of Menopause. Integrated Gynecology & Obstetrics Journal 2: 1–16.
  30. Gabay G, Gere A, Stanley J, Habsburg-Lothringen C, Moskowitz HR (2019) Health threats awareness – Responses to warning messages about Cancer and smartphone usage. Cancer Studies Therapeutics Journal4: 1–10.
  31. Gofman A, Moskowitz HR (2010) Isomorphic permuted experimental designs and their application in conjoint analysis. Journal of Sensory Studies 25: 127–45.
  32. Beck RS, Daughtridge R, Sloane PD (2002) Physician-patient communication in the primary care office: a systematic review. Journal of the American Board of Family Practice15: 25–38.
  33. Brown RF, Butow PN, Dunn SM, Tattersall MH (2001) Promoting patient participation and shortening cancer consultations: a randomised trial. British Journal of Cancer 85: 1273.
  34. Campbell, James D, Hans O, Mauksch, Helen J Neikirk, Hosokawa CM (1990) Collaborative practice and provider styles of delivering health care. Social Science & Medicine 30: 1359–1365.
  35. Cantor N, Kihlstrom JF (2000) Social intelligence. Handbook of intelligence 2: 359–379.
  36. Charlton CR, DearingKS, Berry JA, Johnson MJ (2008) Nurse practitioners’ communication styles and their impact on patient outcomes: an integrated literature review. Journal of the American Academy of Nurse Practitioners 20: 382–388.
  37. Chewning B, Sleath B (1996) Medication decision-making and management: a client-centered model. SocSci Med42: 389–398.
  38. Coeling, Van EH, Cukr PR (2000) Communication styles that promote perceptions of collaboration, quality, and nurse satisfaction. Journal of Nursing Care Quality14: 63–74.
  39. DiMatteo MR (2004) Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. MedicalCare 42: 200–209.
  40. DiMatteo MR, Haskard KB, Williams SL (2007) Health beliefs, disease severity, and patient adherence: a meta-analysis. Medical Care 45: 521–528.
  41. DiMatteo MR, Haskard-Zolnierek KB, Martin LR (2012) Improving patient adherence: a three-factor model to guide practice. Health Psychology Review 1: 74–91.
  42. Dubes R, Jain AK (1980) Clustering methodologies in exploratory data analysis. In Advances in Computers 1: 13–228.
  43. Epstein RM, Street RL (2007) Patient-centered communication in cancer care: promoting healing and reducing suffering. National Cancer Institute
  44. Gabay G (2015) Perceived control over health, communication and patient- physician trust. Patient Education and Counseling98: 1550–1557.
  45. Gabay G (2016) Exploring perceived control and self-rated health in re-admissions among younger adults: A retrospective Study. Patient Education and Counseling 99: 800–806.
  46. Gabay G, Moskowitz HR (2012)the algebra of health concerns: implications of consumer perception of health loss, illness and the breakdown of the health system on anxiety. International Journal of Consumer Studies36: 635–646.
  47. Gabay G, Zemel G, Gere A, Zemel R, Papajorgji P, et al. (2018) On the threshold: What concerns healthy people about the prospect of cancer.Cancer Studies and Therapeutics Journal 3: 1–10.
  48. Gabay G, Gere A, Stanley J, Habsburg-Lothringen C, Moskowitz HR(2019) Health threats awareness – Responses to warning messages about cancer and smartphone Usage. Cancer Studies Therapy Journal4: 1–10.
  49. Gabay G, Gere A, Zemel G, Moskowitz D, Shifron R, et al. (2019) Expectations and attitudes regarding chronic pain control: An exploration using Mind Genomics. Internal Medicine Research Open Journal4: 1–10.
  50. Gabay G, Gere A, Moskowitz HR (2019) Uncovering communication messages for health promotion: The case of arthritis. Integrated Journal of Orthopedic Traumatology2: 1–13.
  51. Gabay G, Gere A, Moskowitz HR. (2019) Understanding effective web messaging – The Case of Menopause. Integrated Gynecology & Obstetrics Journal 2: 1–16.
  52. Gabay G, Gere A, Stanley J, Habsburg-Lothringen C, Moskowitz HR (2019) Health threats awareness – Responses to warning messages about Cancer and smartphone usage. Cancer Studies Therapeutics Journal4: 1–10.
  53. Gofman A, Moskowitz HR (2010) Isomorphic permuted experimental designs and their application in conjoint analysis. Journal of Sensory Studies 25: 127–45.
  54. Haskard-Zolnierek KB, DiMatteo MR (2009) Physician communication and patient adherence to treatment: a meta-analysis. Medical care 47: 826.
  55. Haynes R, Ackloo E, Sahota N, McDonald H, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database of Systematic Review 2: CD000011.
  56. Haynes RB, Yao X, Degani A, Kripalani S, Garg A, et al.(2005) Interventions to enhance medication adherence. Cochrane Database Systematic Review 4
  57. Kreuter MW, Strecher VJ, Glassman B (1999) One size does not fit all: the case for tailoring print materials. Annals of behavioral medicine 21: 276.
  58. Levinson W, Lesser CS, Epstein RM (2010) Developing physician communication skills for patient-centered care. Health affairs 29: 1308–1310.
  59. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J. Med 353: 487–497.
  60. Petty RE, Cacioppo JT(2012) Communication and persuasion: Central and peripheral routes to attitude change. Springer Science & Business Media 6.
  61. Ratanawongsa N, Karter AJ, Parker MM, Lyles CR, Heisler M, et al. (2013) Communication and medication refill adherence: the Diabetes Study of Northern California. JAMA internal medicine 11: 173–210.
  62. Rao JK, Anderson LA, Inui TS (2007) Communication interventions make a difference in conversations between physicians and patients: a systematic review of the evidence. Med Care 45: 340–349.
  63. Rosenthal R, Rosnow R (2007) Essentials of behavioral research: methods and data analysis. McGraw-Hill.
  64. Sabate E (2003) Adherence to long-term therapies: Evidence for action. Geneva: World Health Organization.
  65. Schmid KL, Rivers SE, Latimer AE, Salove P (2008) Targeting or tailoring?. Marketing health services 28: 32–37.
  66. Squier RW (1990) A model of empathic understanding and adherence to treatment regimens in practitioner-patient relationships. SocSci Med 30: 325–339.
  67. Stewart MA (1984) what is a successful doctor-patient interview? A study of interactions and outcomes. SocSci Med 19: 67–175.
  68. Tulsky JA (2005) Interventions to enhance communication among patients, providers, and families. Journal of palliative medicine 8: 95.
  69. Vermeire E, Hearnshaw H, Van Royen P (2001) Patient adherence to treatment: three decades of research, a comprehensive review. J Clin Pharm Ther26: 331–342.
  70. Williams-Piehota P, Schneider TR, Pizarro J, Mowad L, Salovey P (2003) Matching health messages to information-processing styles: Need for cognition and mammography utilization. Health Communication15: 375–392.
  71. Zolnierek KB, DiMatteo MR(2009) Physician communication and patient adherence to treatment: a meta-analysis. Medical care 47: 826.